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ABSTRACT OF THE DISSERTATION
Neuroprotective Molecules and Strategies in a Rat Model of Neonatal Hypoxic Ischemic
Encephalopathy
by
Brandon J Dixon
Doctor of Philosophy, Graduate Program in Physiology
Loma Linda University, December 2016
Dr. Jiping Tang, Chairperson

Neonatal hypoxic ischemic encephalopathy (HIE) is a devastating disease that
primarily causes neuronal and white matter injury and is among the leading cause of
death among infants. Currently there are no well-established treatments; thus, it is
important to understand the pathophysiology of the disease and elucidate complications
that are creating a gap between basic science and clinical translation. In the development
of neuroprotective strategies and translation of experimental results in HIE, there are
many limitations and challenges to master based on an appropriate study design, drug
delivery properties, dosage, and use in neonates. Since there are no established therapies
for HIE and it is critical to develop treatments that provide protection after HIE. In three
separate studies we evaluated the efficacy of interferon beta (IFNβ), granulocyte-colony
stimulating factor (G-CSF), and osteopontin (OPN) in reducing apoptosis and
inflammation following neonatal hypoxic ischemic encephalopathy and have outlined the
cellular pathways involved in their abilities to provide neuroprotection. Our work showed
that intranasal administration of IFNβ was able to be detected in the central nervous
system, reduce brain infarction volumes, and improve neurological behavior tests 24
hours after HIE. Administration of G-CSF was able to play a pivotal role in attenuating

xvi

neuroinflammation and BBB disruption 48 hours following HIE. Similarly, OPN was
able to decrease blood-brain barrier permeability and brain edema after HIE. In addition,
we have also reviewed and discussed the current literature on the pathophysiology,
potential intervention sites, novel neuroprotecitve molecules, clinical trials, and future
directions concerning HIE.
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CHAPTER ONE
NEUROPROTECTIVE STRATEGIES AFTER NEONATAL HYPOXIC
ISCHEMIC ENCEPHALOPATHY
Abstract
Neonatal hypoxic ischemic encephalopathy (HIE) is a devastating disease that
primarily causes neuronal and white matter injury and is among the leading cause of
death among infants. Currently there are no well-established treatments; thus, it is
important to understand the pathophysiology of the disease and elucidate complications
that are creating a gap between basic science and clinical translation. In the development
of neuroprotective strategies and translation of experimental results in HIE, there are
many limitations and challenges to master based on an appropriate study design, drug
delivery properties, dosage, and use in neonates. We will identify understudied targets
after HIE, as well as neuroprotective molecules that bring hope to future treatments such
as melatonin, topiramate, xenon, interferon-beta, stem cell transplantation. This review
will also discuss some of the most recent trials being conducted in the clinical setting and
evaluate what directions are needed in the future.

Introduction
Neonatal Hypoxic Ischemic Encephalopathy
Neonatal hypoxic ischemic encephalopathy (HIE) is a devastating disease that
primarily causes neuronal and white matter injury. HIE has tremendous detrimental
effects on the developing brain and is among the leading causes of death among infants,
as well as the major underlying cause of seizures in term infants [1,2,3]. Although there
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have been major advances in modern technology and an increased understanding of fetal
and neonatal pathologies, HIE is still a serious condition that is unresolved and causes
significant mortality and long-term morbidity [4,5,6,7].
Neonatal HIE can also be characterized as an injury that occurs in the immature
brain, resulting in delayed cell death via excitotoxicity, inflammation, and oxidative
stress [4]. These adverse events in the developing brain often lead to long lasting
detrimental neurological defects later on in life such as mental retardation, epilepsy,
cerebral palsy, learning disabilities, and other neurophysiological handicaps [8]. Care for
newborn infants at risk for hypoxia ischemia is a priority in health care and understanding
the pathophysiology of hypoxic ischemic brain injury is quite essential to the design of
effective interventions [9].
Before the advent of hypothermia, clinicians were not able to provide much care
to neonates suffering from HIE besides systemic supportive care [10]. It is necessary to
explicate interventions that will rid young children’s lives of this form of stroke. Thus,
this review aims to characterize the current pathophysiology of HIE, and describe and
elucidate complications that are creating a gap between basic science and clinical
translation. In addition, we aim to analyze promising neuroprotective strategies after HIE
and prognosticate how treatment strategies will change and what new therapeutic
strategies are on the horizon.

Incidence and Prognosis of HIE
Neonatal hypoxic ischemic encephalopathy is of great importance since it is the
major cause and contributor to global infant mortality and morbidity [11]. The incidence
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of neonatal HIE in the United States is 2–3 in 1000 live births, with evidence of
incidences being up to 6 births in 1000 live births [11]. Underdeveloped countries have
even reported incidences up to 26 per 1000 live births [10]. About 20%–25% of term
newborn infants die during the neonatal period and about 25% of those that survive
develop permanent neurological disabilities. Patients with mild grades of encephalopathy
are generally reported to have normal cognitive functions by school age. While patients
with moderate grading are associated with a spectrum of long-term disabilities and
significant motor and cognitive disabilities [10].

Clinical Presentation
Neonatal hypoxic ischemic encephalopathy usually presents clinically in the
earliest days of life in a term infant and can be characterized by difficulty initiating and
maintaining respiration, depression of tone and reflexes, subnormal levels of
consciousness, and multiple seizures [10].
Since HIE is the major underlying cause of seizures in term infants, a large
variety of seizures may present [12]. Subtle, clonic, tonic, myoclonic that are focal,
multifocal, or generalized are the most common types of seizures that present [13,14,15].
In the perinatal period hypoxemia, ischemia, and other impairments to the exchange of
respiratory gases often give rise to asphyxia. Thus, neonatal HIE is described as acute
intrapartum events that cause moderate to severe neonatal encephalopathy, metabolic
acidosis in fetal umbilical arterial blood obtained at delivery, spastic or dyskinetic
quadraparesis, and absence of other causes of cerebral palsy [16]. It is also critically
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important to eliminate other causes of neonatal encephalopathy in order to prevent delay
in diagnosis and neuroprotective intervention [17].
In order to classify neonatal HIE and the degree of injury, the Sarnat 3 stage
grading system is used and widely accepted. This system consists of three stages ranging
from mild, moderate, and severe, all based on clinical symptoms described above, along
with electroencephalogram evaluation [18].

Current Therapeutic Strategies
Presently, there are no well-established effective therapies for neonatal HIE [19].
Hypothermia is a method of protection that is used to treat full term neonates with
moderate to severe HIE. Along with hypothermia, comprehensive clinical care of
mechanical ventilation, physiological and biochemical monitoring, neuroimaging, seizure
detection and monitoring, and neurological consultation are also included. Although
hypothermia does provide some protection, only 1 in 6 infants benefit from hypothermia
[20]. There is an area of uncertainty involving hypothermia in regards to depth and
duration of cooling, and information involving premature infants born less than 35 weeks
of gestational age. Thus, it is critical to have an appropriate treatment to provide
protection to neonates suffering from HIE [21].

Potential Intervention Targets
Since the pathophysiology of HIE injury is quite complex, there are a myriad of
potential interventional targets following HIE where prevention of cellular damage can
occur [22] (Figure 1). Targeting impaired function sites like the neurovascular unit,
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attempting to quell apoptosis, inflammation, or promoting neurogenesis and angiogenesis
are all strategic points of importance [10,23]. Although targets such as apoptosis or
necrosis have been previously explored, there are other areas of importance that have
been understudied [24,25]. We will now delve into the pathophysiology and discuss some
promising understudied intervention sites.
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Figure 1. Interventional Targets Following Hypoxic Ischemic Encephalopathy (HIE). A
summary of potential interventional targets following HIE along with molecules that can
exert multiple properties. Interventional targets consist of Excitotoxicity, Oxidative Stress,
Blood Brain Barrier Disruption, Apoptosis, Inflammation, Angiogenesis, and
Neurogenesis. Multiple target sites suggest that a multi-targeted approach is beneficial after
HIE.
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Pathophysiology
The next phase that follows is a primary energy failure phase that occurs at the
cellular level (Figure 2a). Since there is a loss of oxygen that is readily available to the
brain, cellular energy metabolism shifts to a dependency upon anaerobic metabolism.
This reliance upon anaerobic metabolism pathways leads to the collection of lactic acid
and depletion of adenosine triphosphate (ATP) [27]. The loss of cellular homeostasis also
leads to an intracellular accumulation of sodium, calcium, water, and excitatory
neurotransmitter release causing an “excitotoxic-oxidative cascade”. Increasing cellular
influx of calcium also occurs as a consequence of excessive stimulation of
neurotransmitter receptors and membrane depolarization [28,29].
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Figure 2. Vasculature Changes and Primary Energy Failure (Phase I) Legend: A visual
representation of the first phase of HIE. Detrimental changes to the vasculature following
an HIE insult lead to loss of autoregulation and severe lowering of the systemic arterial
blood pressure. This causes a decrease in oxygen, depletion of ATP, as well as increases
in excitotoxicity, intracellular calcium, oxidative stress, and mitochondrial dysfunction; (b)
Secondary Energy Failure (Phase II). Legend: A schematic representation of the second
phase of HIE reveals continued excitotoxicity, oxidative stress, and mitochondrial
dysfunction; (c) Chronic Inflammation (Phase III). A pictorial representation of the third
phase of HIE shows injury to microglia, neurons, and astrocytes leads to continuous release
of cytokines and other detrimental factors causing chronic inflammation which in turn
leads to epigenetic changes, as well as impairments of synaptogenesis, axonal growth, and
neurogenesis.
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Further influx of calcium also leads to increased activation of lipase, causing a
release of fatty acids, and increased activation of neuronal nitric oxide synthase giving
rise to free radical production and mitochondrial dysfunction [26]. As a consequence,
mitochondrial dysfunction ultimately signals pathways of apoptotic or necrotic cell death.
Apoptotic cell death is believed to occur when energy supplies are not completely
exhausted, while necrotic cell death occurs when energy supplies are no longer available
[27].
A second energy failure phase also occurs 6–48 h after an episode of hypoxia
ischemia [30]. The second energy failure phase also results in the detrimental release of
excitatory neurotransmitters and free radicals as well as depletion of high phosphate
reserves, but differs from the primary energy failure phase since it is independent of
cerebral acidosis [30,31].
A third phase where deleterious factors cause further damage and potentiates
injury and worsens outcomes has recently been proposed. This third phase is thought to
include mechanisms of inflammation and epigenetic changes that lead to an impairment
or alteration of axonal growth, neurogenesis, and synaptogenesis [29].

Blood-Brain Barrier
The neurovascular unit, also referred to as the blood-brain barrier (BBB), consists
of the basement membrane, capillary endothelial cells, tight junctions, pericytes, and
astrocytes [32]. It is believed that all the components that comprise the BBB are
important for stability and proper functioning [33]. Thus, injury to the cerebrovasculature
and the BBB after HIE leads to detrimental effects since it is an essential diffusion barrier

9

required for normal functioning of the central nervous system [33]. In an observational
study of term neonates with HIE, it was found that BBB permeability is a contributing
factor to HIE [34]. In order to assess permeability of the BBB in this study, the
cerebrospinal fluid albumin to plasma albumin ratio was measured in 43 HIE neonates
and was compared with 20 normal gestational age and gender-matched healthy infants
without HIE. The results showed that plasma albumin levels were similar in neonates
with and without HIE. However, cerebral spinal fluid (CSF) albumin levels were 5 times
higher in infants with HIE when compared with controls indicating permeability of the
BBB [32,34,35].
It is believed that cytokines, nitric oxide, and vascular endothelial growth factor
(VEGF) help regulate mechanisms that lead to tight junction disruption and increased
BBB permeability [33]. Increased levels of proinflammatory cytokines have also been
observed in animal brains after global and focal ischemia as well as in cerebrospinal fluid
of stroke patients [33].
After HIE it is postulated that there are biphasic temporal patterns of BBB
opening. Numerous in vitro and in vivo studies have revealed that VEGF and matrix
metalloproteinases (MMP) are involved in the initial opening of the BBB within hours of
an hypoxic-ischemic event [32]. While the second opening, occurring around 6–24 h,
involves the activation of microglia and astrocytes which release proinflammatory
cytokines that induces MMPs and cyclooxygenases triggering protease destruction and
reactive oxygen species (ROS) production respectively [32]. Once the barrier is
disrupted, detrimental events can be further exacerbated by the infiltration of neutrophils
and monocytes from the systemic compartment.
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Although many adverse outcomes occur once the BBB is permeable, there are
experimental studies that show that stabilizing the BBB and reducing inflammatory
markers after hypoxic ischemic events as well as HIE may be beneficial [36,37,38,39,40].
For example, a study exploring the mechanisms of granulocyte-colony stimulating factor
(G-CSF) as a treatment after a neonatal rat model of HIE, demonstrated that G-CSF
elicited BBB stabilization by G-CSF receptor stimulation and activation of the
phosphoinositide 3-kinase (PI3K)/Akt pathway. The enhancement of the BBB occurred
in endothelial cells through increases in tight junction proteins, claudin 3 and claudin 5,
in addition to decreases in vascular cell adhesion protein 1 (VCam-1) and intercellular
adhesion molecule 1 (ICam-1) adherens proteins [41].
Similarly another study utilizing a neonatal rat model administered plasminogen
activator inhibitor-1 following an HIE insult. This group was able to demonstrate that
inhibition of tissue plasminogen activator (tPA) was able to prevent MMP activation,
prevent HIE-tPA induced opening of the BBB, and decrease tPA-converted plasmin
activities as a protease that normally degrades the extracellular matrix and the BBB [42].
Some strides have been made, yet further investigations are needed to better
understand BBB integrity after HIE [35]. It has been suggested that endothelial cells may
be more susceptible to oxygen deprivation, while astrocytes and pericytes are tolerant of
sole oxygen deprivation, indicating that a more complete understanding of the cellular
relationship that comprises the BBB may be critical to formulating strategies of
protection following hypoxic ischemic events [43]. Also, more recent knowledge seems
to indicate that the BBB may be more stable during the developmental period than
maturation [35]. Thus, any and all information regarding the mechanisms of BBB
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formation and disruption will help in constructing strategies of BBB protection.

Angiogenesis
Angiogenesis is characterized as the process involving the growth of new vessels
that extend the existing blood circulation into avascular regions. The angiogenesis
process consists of vascular basal lamina formation, proliferation and migration, and
tubular formation of migrating cells. Some findings suggest that angiogenesis is activated
after acute insult in the neonatal brain [44]. One study comparing asphyxiated newborns
without brain injury, asphyxiated newborns with brain injury, and healthy newborns
discovered that angiogenesis pathways maybe dysregulated after HIE. This dysregulation
was evidenced by the observation that asphyxiated newborns with brain injury had
decreased expression of insulin-growth factor binding protein-1, -4, and -6, which are
anti-angiogenic proteins. While asphyxiated newborns that did not develop brain injury
showed increases in fatty acid binding protein 4, glucose-6-phosphate isomerase,
expression of neuropilin-1 (a vascular endothelial growth factor receptor-2 co-receptor),
and receptor tyrosine-protein kinase erbB-3, which are proteins associated with
endothelial cell survival, proliferation, and migration [45]. Thus, angiogenesis seems to
be a viable target in newborns with HIE [44]. In the adult brain, angiogenesis is a key
repair mechanism after a hypoxic ischemic event. However, several factors concerning
angiogenesis remains to be elucidated after injury in term newborns [44]. Further studies
to discover how angiogenesis can be activated to enhance brain repair after HIE in
newborns are essential to creating viable strategies on how to improve functional and
structural recovery after injury [44]. One study indicated that angiogenesis is activated
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after HIE injury by observing hyperfusion measured by magnetic resonance imaging
(MRI) during the first month [44]. It has also been shown that angiogenesis could be
induced by the transplantation of CD34+ cells from umbilical cord blood and that this
improvement is beneficial [46]. Together the data suggests that the neovascularization
mechanisms are essential for survival and may be a potential therapeutic site after stroke.

Neurogenesis
Neurogenesis is comprised of cell proliferation, migration and differentiation
[47]. It is believed that neurogenesis continues even throughout adulthood. The site for
neurogenesis occurs in the subventricualar zone and subgranular layer of the
hippocampal dentate gyrus, where the local environment tightly regulates neurogenesis.
Although there is evidence that suggests that neurogenesis increases after injuries such as
HIE, the endogenous repair mechanisms do not resolve the brain damage that occurs
[48,49,50]. Ong et al. observed increases of doublecortin, a microtubule-associated
protein only expressed in immature neurons, with immunostaining in the subventricular
zone ipsilateral to HIE-induced lesioning one to three weeks post injury. However, after
the fourth week there were no identifiable newly formed mature striatal neurons,
suggesting that there was limited neurogenesis at this time period. These results also
suggest depletion of the neuronal progenitor pool since they are more vulnerable to HIE
than SVZ stem cells or that the environment is not conducive to the maturation and
survival of newly formed neurons since there maybe a lack of trophic support [51]. Thus,
aiding or boosting the endogenous repair mechanisms after brain injuries may restore
function. Therefore, understanding the molecular and cellular mechanism of neurogenesis
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and whether or not these mechanisms can be clinically applicable presents neurogenesis
as a prime therapeutic target [50,51].
There have been a number of promising stem cell therapy experiments that
promote neurogenesis after injury. For example, van Velthoven et al. demonstrated that
bone marrow derived mesenchymal stem cells treatment after HIE was able to increase
neurogenesis and formation of new oligodendrocytes, evidenced by NeuN-positive and
olig2-positive cells [52]. Again, it is quite important that more studies are conducted to
optimize and elucidate mechanisms following injury. Discovering and understanding the
factors that promote neurogenesis during normal physiological conditions as well as the
impairment that occurs during brain damage are key questions that need to be determined
[50,53].

Autophagy
After HIE, there is evidence of differential cellular death mechanisms often
occurring in different cells. One cellular death mechanism that has increased scientific
interests and has been recently implicated in HIE has a potential therapeutic target is
autophagy [24,54]. Autophagy is a lysosomal pathway for intracellular degradation of
macromolecules and organelles that plays an important part to maintaining cellular
survival and homeostasis [55]. Since autophagy is a tightly regulated process,
controversy of whether or not autophagy provides beneficial effects after HIE currently
exists [56]. There are some experiments that describe pharmacological inhibition of
autophagy being neuroprotective, while others have shown that inducing autophagy
immediately after injury may be an endogenous neuroprotective mechanism [4].
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For example, Chen et al. demonstrated that brain-derived neurotrophic factor
(BDNF) with a concentration range of 50 to 200 ng/mL protects neurons from hypoxia
injury in vitro via the induction of autophagy [57]. It was shown that BDNF could induce
autophagy through the PI3K/Akt/mammalian target of rapamycin (mTOR) pathway. In
this study, activation of mTOR complex 1 lead to phosphorylation of ribosomal protein
S6 kinase (p70S6K), a controller of protein translation, which ultimately induced
autophagy and exerted protective effects [57]. Conversely, a study evaluating the effects
of lithium in an in vivo model of neonatal HIE brain injury found that lithium was able to
inhibit post-ischemic autophagy after 72 h. This reduction of autophagy was indicated by
decreased number of LC3-positive cells in lithium-treated animals 72 h post-HIE. Given
these results, it is unclear if a reduction of autophagy occurred as a secondary effect to
lithium induced neuroprotection since there is less cellular debris and damage
contributing to autophagy processing or if lithium directly inhibited autophagy [55].
Mixed results involving autophagy suggests that deleterious or neuroprotective effects
depend upon specific regions, the severity of the insult, and the timing of activation [4].
Over the past decades, much has been learned about autophagy; however, more studies to
elucidate exact mechanisms remain, especially following neurodegenerative insults and
diseases [54].

Potential Novel Molecules and Strategies for Neuroprotection after HIE
Over the past decade, clinical and basic science research in neonates has achieved
huge progress in neuroprotective and neurointensive care, and established hypothermia as
the standard of care treatment for neonatal HIE. Although there has been much progress,
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further investigation is needed to discover adjuvant neuroprotective strategies [58]. This
is also important for designing clinical and experimental studies since therapeutic targets
might alternate in the phases of HIE, in addition to the physiological development
changes that occurs in neonates over time [29]. We will now discuss some molecules that
are neuroprotective and are currently being evaluated in experimental translational
studies (Table 1) and clinical trials (Table 2) for therapeutic potential after HIE.
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Table 1. Neuroprotective molecules evaluated in experimental translational studies after
HIE. Summary of neuroprotective molecules used in experimental translational studies and
their proposed mechanisms of action associated with HIE.
Molecules Studied
Osteopontin (OPN)

Interferon Beta (INFβ)

c-Jun N-terminal kinases (JNKs)

Prophylactic barbiturates

Melatonin

Edaravone

Possible Effects Related to
Neuroprotection
OPN repairs brain injury after neonatal
HIE by mediating regulation of cerebral
cell proliferation, cell survival, and
oligodendrocyte differentiation after
injury [59]
Reduce TNF-α levels, proliferation and
activation of T-cell lymphocytes, and
pro-inflammatory cytokines produced by
T-cells; Blood Brain Barrier integrity [60]
JNKs play a role in regulation of
apoptosis [61]; Reductions in early
neuronal
damage
[62];
Reduced
inflammation and inhibition of apoptotic
neuronal loss [63]
Diminishes
moderate
to
severe
neurodevelopmental impairment or death
(HIE undergoing whole-body cooling)
[64]; Multivariate analysis suggested its
use to be associated with better outcomes
[64]
Antioxidant, anti-inflammatory, and antiapoptotic properties [65,66]; Protect the
brain independently or in concert with
therapeutic hypothermia [67]; Reducing
oxidative stress and improved survival
with favorable
neurodevelopmental
outcome at 6 months of age in
combination with hypothermia [68]
Edaravone may inhibit the number of
apoptotic neuronal cells and 8-OHdG
expression within 48 h after HI insult
[69]; Inhibits lipid peroxidation in
neonatal HIE rat model [70]; Scavenger
that inhibits both lipid and DNA
peroxidation [71]

17

Table 2. Neuroprotective molecules evaluated in current clinical trials involving HIE.
Summary of neuroprotective molecules that are currently being studied in HIE clinical
trials and their proposed mechanisms of action.
Molecules Studied

Erythropoietin (EPO)

Allopurinol

Xenon

Prophylactic barbiturates

Topiramate (TPM)

Magnesium Sulfate (MgSO4)

Cord blood

Possible Effects Related to
Neuroprotection
Associated with anti-inflammatory, antiexcitotoxic, anti-oxidative, and anti-apoptotic
properties [72,73,74]; Vasogenic and proangiogenic functions [73]; Hypoxia-induciblefactor-1 mediates increase in EPO expression
[75,76]
Neuroprotection in postnatal day 7 rats after
HI [77]; Post hoc analysis revealed a
potential benefit in treatment of females [78].
May trigger neurodegeneration in the
developing brain. Thus, the safety of a
newborn injured brain is not expected [79];
Neuroprotective in adult rats in transient
brain ischemia [79]; Limited protection
when given alone but protection for up to 30
days when given in combination with
hypothermia (neonatal rodents) [80]
Diminishes
moderate
to
severe
neurodevelopmental impairment or death
(HIE undergoing whole-body cooling) [64];
Multivariate analysis suggested its use to be
associated with better outcomes [64]
AMPA and Kainate receptors inhibition
[81,82,83]; Blockade of Na channels, high
voltage-activated calcium currents, carbonic
anhydrase isoenzymes and mitochondrial
permeability transition pore [84,85,86,87];
TPM in concert with melatonin decreases
infarcted volume and apoptosis in neonatal
HI rat model [88]; Pretreatment significantly
reduced the brain damage and subsequent
cognitive impairments [89]
Controversies exist regarding its efficacy in
protecting the brain in term infants who may
suffer encephalopathy [90]
Controversies exist regarding its efficacy in
protecting the brain in term infants who may
suffer encephalopathy [91]
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Experimental Translational Studies
Osteopontin
Osteopontin (OPN) is a mutifunctional glycoprotein with increased upregulation
in the brain after neonatal HIE. OPN has both pro- and anti- inflammatory properties;
thus, its exact role in injury is not well predicted [59,98,99]. OPN repairs brain injury
after neonatal HIE by mediating regulation of cerebral cell proliferation, cell survival,
and oligodendrocyte differentiation after injury [100]. According to Chen and colleagues,
OPN-induced neuroprotection was associated with cleaved caspase-3 inhibition and antiapoptotic cell death, thereby improving long-term neurological function against neonatal
HIE brain injury [101]. However, a recent study done by Bonestroo and colleagues
demonstrated that intranasal, intraperitoneal (i.p.), and intracerebral administration of a
small TAT-OPN peptide was neither neuroprotective by measuring the anatomical
reduction of the HIE induced brain injury, nor beneficial in reducing sensorimotor
behavioral deficits [102]. Endogenous expression of OPN was shown to be highest in the
brain at age 0 with continuous reductions until day 21 during development. After HIE
injury, endogenous OPN expression increased and peaked at 48 h. Exogenous OPN
decreased infarct volume and improved neurological outcomes 7 weeks after HIE injury
[101].

Interferon Beta
Inflammation plays an important role in the pathology of HIE, interventions at the
inflammation portion of the disease can potentially be beneficial [19]. Thus, it is
plausible that the positive immunomodulatory effects of interferon beta (IFNβ) as seen in
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an inflammatory environment such as multiple sclerosis (MS) will also have a therapeutic
effect in the neonatal HIE model. In experimental models of MS, IFNβ has been shown
to reduce tumor necrosis factor alpha (TNF-α) levels, proliferation and activation of Tcell lymphocytes, and pro-inflammatory cytokines produced by T-cells [60]. Intrastriatal
injections IFNβ has been shown to preserve the BBB integrity, decrease infarct size, and
block the infiltration of inflammatory cells in a middle cerebral artery occlusion model
[103]. In a model of transient focal stroke, it was reported that intravenous tail injections
of IFNβ failed to provide protection. It appears that IFNβ is unable to cross BBB; thus,
methods to circumvent the BBB are needed in order for IFNβ to be effective [104].

c-Jun N-Terminal Kinases
c-Jun N-terminal kinases (JNKs) activation is associated with an assortment of
environmental stressors and for that reason they are known as stress activated protein
kinases [105,106]. Through phosphorylation and modification of proteins residing in the
mitochondria, JNKs play a role in regulation of apoptosis [61]. Nijboer and colleagues
demonstrated reductions in early neuronal damage in P7 rats at 0 and 3 h after HIE [62].
They injected intraperitoneally TAT-JBD, a JNK inhibitor, in a neonatal model of HIE
brain injury. Post insult administration reduced brain damage and lasted up to 14 weeks
post-HIE. Furthermore, sensory, cognitive, and behavioral benefits were associated with
the 50% anatomical cerebral improvements found in their study. These results indicated
that the activity of JNK in the brain was inhibited effectively by TAT-JBD treatment
[107]. In 2013 Nijboer and colleagues also demonstrated that inhibition of
phosphorylation of mitochondrial JNK may lead to preventing early loss of mitochondrial
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integrity, consequently leading to reduced inflammation and inhibition of apoptotic
neuronal loss. Up-regulation of anti-apoptotic mitochondrial proteins also played a
crucial role in maintaining neuroprotection [63].
The TAT-JBD peptide may serve as a treatment option for neonatal HIE due to its
promising results in reducing neuronal damage and loss of mitochondrial activity through
early JNK inhibition, with overall improvements in anatomical outcomes, therefore
improving cognitive and behavioral results post-HIE. The present study shows that early
JNK inhibition by the short-lived TAT-JBD peptide may be a promising therapy for
neonatal HIE by conferring long-term anatomical and behavioral improvements [107].

Prophylactic Barbiturates
A retrospective study by Donald F. Meyn, Jr. and colleagues [64] analyzed the
effects of prophylactic administration of phenobarbital to infants with HIE. They found
that phenobarbital administration to infants with HIE undergoing whole-body cooling
diminishes moderate to severe neurodevelopmental impairment or death. Despite their
small sample size, they found that this combination diminishes clinically detectable
seizures. On the other hand, their study failed to improve neurodevelopmental outcomes
significantly by univariate analysis. However, multivariate analysis suggested its use to
be associated with better outcomes. Though the most effective dose, most effective
timing of administration, and the most effective drug are not known, the treatment
combination used by Meyn Jr. and colleagues may help disrupt the cascade of injury.
Therapeutic interventions enabling prevention or reduction in hypoxia-induced
brain damage before or during an earlier stage of free-radical production will require
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continued investigation for optimal effectiveness [108]. These results and findings set the
stage for a large and multicenter randomized-control trial that includes a long term follow
up analysis to further test the incremental benefit of prophylactic anticonvulsant therapy
in the setting of hypothermia [64].

Melatonin
Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous indolamine and
another scavenger that has shown promising effects in the treatment of HIE. It has
antioxidant, anti-inflammatory, and anti-apoptotic properties [65]. Melatonin freely
crosses the placenta and the blood-brain barrier making it an attractive agent for
neuroprotection. In an asphyxia animal model it has been shown to protect the brain
independently [66] or in concert with therapeutic hypothermia [67]. Aly and colleagues
demonstrated that the combination of melatonin and therapeutic hypothermia in infants
with moderate to severe HIE was efficacious in reducing oxidative stress and improved
survival with favorable neurodevelopmental outcome at 6 months of age [68].
Intravenous use of melatonin showed efficacy and feasibility when used in neonates with
HIE who were receiving whole body therapeutic hypothermia [68]. With its effectiveness
for both pre-term and term infants [109] it holds considerable promise as an adjunct
therapy [110] and results from various studies suggest combination therapy as the most
effective. Optimal dose, route, and duration of administration are still parameters that
need to be researched in depth in order to help in clinical translation.
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Edaravone
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a free scavenger that is
thought to be useful for the treatment of acute cerebral stroke. Edaravone is believed to
interact with peroxyl and hydroxyl radicals creating a radical intermediate that forms
stable oxidation products [69,70]. Ni X. and colleagues also demonstrated the benefits of
edaravone as an antioxidant agent in HIE. They observed that systemic administration of
edaravone 30 min after resuscitation from HIE can salvage neurons in the striatum in a
large animal model of neonatal HIE [71]. Furthermore another study showed that
intraperitoneal administration of edaravone after HIE for consecutive days improved
memory and learning ability when given in the acute phase of HIE [111].

Current Clinical Trial Studies
Erythropoietin
Erythropoietin (Epo) is a 34 kilodalton glycoprotein with pleotropic properties.
Epo has been reported to have effects on a variety of receptor-mediated and cell-specific
mechanisms that are beneficial and essential after HIE. Epo has been associated with
anti-inflammatory, anti-excitotoxic, anti-oxidative, and anti-apoptotic effects as well as
promoting neurogenesis and angiogenesis [72,73,74]. Epo is expressed in both human
and animal brains in its early development but decreases gradually after birth [112].
Hypoxia-inducible factor-1 mediates the increase of Epo after HIE in the brain,
leading not only to an increase in Epo expression but also an increase in the Epo receptor
in neurons, astrocytes, and microglia [75,76]. Epo levels are increased in newborn infants
with HIE in the cerebrospinal fluid despite the absence of exogenous Epo treatment
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[112]. In the setting of HIE there is an increase in permeability of the blood brain barrier
[113,114,115], allowing high doses of Epo to increase its levels in the CSF
[113,114,115,116]. Studies have shown that neonatal rats with HIE injuries have
histological and functional improvements following high-doses of Epo and that multiple
doses reduces infarct volumes in a dose-dependent manner [118]. Kumral et al.
demonstrated that a single dose of Epo (1000 U/kg i.p.) immediately after neonatal
hypoxic–ischemic insult diminished long-term spatial memory deficits. In addition, a
treatment group that received Epo but did not undergo HIE, showed no differential
effects concerning learning or memory from the treatment [119]. One clinical study also
showed that Epo 1000 and 2500 U/kg per dose intravenously administered along with
hypothermia achieved and surpassed plasma concentrations that provided neuroprotection
in animal models [118]. Furthermore a study evaluating middle cerebral artery occlusion
in neonatal rats found that three daily doses of Epo (1 U/g, i.p. each) caused increases in
hemispheric volume and its sub regions, as well as spatial learning and memory [120].
There have been several completed clinical trials concerning Epo after HIE injury
[114,121,122,123]. Currently there are two active clinical trials (NCT01913340 and
NCT01732146) examining Epo in combination with hypothermia in infants with HIE.
The “Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn
Brain Injury” study (NCT01913340) assesses an Epo dose of 1000 U/kg/dose IV × 5
doses. While the “Efficacy of Erythropoietin to Improve Survival and Neurological
Outcome in Hypoxic Ischemic Encephalopathy” study (NCT01732146) evaluates Epo
intravenous injections (5000 U/0.3 mL) 1000 to 1500 U/kg/dose three times given every
24 h with the first dose within 12 h of delivery.
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Epo exerts neuroprotection through phosphorylation of its receptor and Janus
Kinase 2, which provides a docking complex for intracellular signaling proteins including
PI3K as well as Akt, signal transducer and activator of transcription 5 (STAT5), and the
extracellular signal-regulated kinase (ERK). Activating these pathways leads to alteration
of cell proliferation, survival, and differentiation by affecting a number of downstream
targets. For example, Akt limits inflammation [124] and decreases apoptotic cell death.
STAT5 acts on cell survival [125], while the ERK pathway has demonstrated not only to
have anti-apoptotic and anti-inflammatory effects in vitro but also to be essential for
neurogenesis and cell fate commitment [126,127].

Allopurinol
Allopurinol is a xanthine oxidase inhibitor that lowers uric acid concentration in
patients with gout and neoplastic diseases. In addition, allopurinol functions as a chelator
of non-protein bound iron as well as a direct scavenger of hydroxyl radicals, suggesting it
may serve in neuroprotection [128]. Indeed, allopurinol provided neuroprotection in
postnatal day 7 rats after HIE [77]. Even though Benders and colleagues did not show
improvement in outcomes with after-birth asphyxia [129], a recent follow-up study in
human neonates with allopurinol used on term asphyxiated neonates showed benefits on
mortality and severe disabilities at 4–8 years of age [130]. In addition, Kaandorp and
colleagues investigated the pharmacological applicability of allopurinol for intrauterine
neuroprotection after maternal administration. They showed intravenously administered
allopurinol to the mother rapidly crosses the placenta with satisfactory concentrations
reaching the neonate at birth. In addition, it is safe to both the mother and the neonate.
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In 2014, the same group published the results of another clinical trial. Maternal
treatment with allopurinol during fetal hypoxia did not significantly lower neuronal
damage markers in umbilical cord blood. However, post hoc analysis revealed a potential
benefit in treatment of females (NCT00189007) [78]. There is an ongoing study
investigating the reduction in free radical formation after reperfusion with initiation of
this medication during labor, with the intention of reducing free radical induced post
asphyxia brain damage. They hope to demonstrate how allopurinol during asphyxia
reduces post-hypoxic-ischemic reperfusion damage in the newborn (NCT00189007). In
addition, there is another ongoing trial (the European ALBINO trial) that will assess
outcomes at 2 years of life. Studies have shown allopurinol is a viable treatment option
for early fetal neuroprotective therapy during labor, but future studies and clinical
investigation are necessary to further support its effectiveness.

Xenon
Xenon is a potent anesthetic with a low gas partition coefficient. It crosses the
BBB easily and guarantees rapid induction of anesthesia. As an anesthetic it has proven
to be safe in adults and well tolerated [131]. However, a recent review by Istaphanous
and Loepke demonstrated that xenon may trigger neurodegeneration in the developing
brain [132]. Thus, the safety of a newborn injured brain is not expected.
Important neuroprotective effects of Xenon have been demonstrated in adult rats
in transient brain ischemia [79]. In neonatal rodents, it was associated with relatively
limited protection when given alone but did protect for up to 30 days when given in
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combination with hypothermia [80]. Similarly, other studies have also proven this
combination to be beneficial [133,134].
Xenon was reported to be safe for use in a phase II randomized study outcomes
after demonstrating to have similar results as cooling therapy alone [135]. An ongoing
clinical trial (NCT01545271), estimated to be completed in October 2015, aims to
examine the effect of inhaled xenon gas in the treatment of newborn infants with HIE in
combination with cooling, which is the standard treatment of this condition. They
hypothesize that the xenon and cooling combination will produce better neuroprotection
than the standard treatment of cooling alone. Hypothermia plus adjuvant therapies have
been extensively reviewed in two recent publications [136,137]. Based on the preclinical
studies, ongoing trials in neonates include inhaled Xenon and cooling (NCT01545271
and NCT00934700).

Topiramate
Topiramate (TPM) is an anticonvulsant agent with multiple mechanisms of action
[138,139], implying its ability to be a neuroprotective agent. It has neuroprotective
qualities according to previous literature. Its neuroprotective mechanisms appear to be
related not only to AMPA and Kainate receptors inhibition [81,82,83,140,141] but also to
blockade of Na+ channels [84], high voltage-activated calcium currents [85], carbonic
anhydrase isoenzymes [86], and mitochondrial permeability transition pore [87].
Even though no clinical studies have been published to prove an additive or
synergistic action of TPM in concert with hypothermia in newborns, ongoing clinical
trials (NCT01765218), Topiramate in Neonates Receiving Whole Body Cooling for
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Hypoxic Ischemic Encephalopathy, are investigating whether topiramate improves the
outcomes of babies with neonatal hypoxic encephalopathy who are receiving whole body
cooling. This trial is to be completed in 2017.
TPM in concert with melatonin decreases infarcted volume and apoptosis in
neonatal HIE rat model [88]. In addition, Noh and colleagues [89] reported that i.p. or per
oral topiramate pretreatment significantly reduced the brain damage and subsequent
cognitive impairments induced by hypoxia-ischemia in neonatal rats. Similarly, it leads to
dose dependent and long lasting neuroprotection in the excitotoxic newborn mouse model
[141]. Topiramate is able to provide neuroprotection by increasing survival of preoligodendrocytes, decreasing neuronal apoptosis, inhibiting microglial activation and
astrogliosis, and decreasing seizure activity.
Melatonin and topiramate, acting on different stages of HIE, used alone or in
combination, significantly decreased the percent infarcted area, and apoptotic cell death
in neonatal HIE rat model. It is necessary to investigate different doses and application
times of these agents as combination therapy in order to provide more effective
neuroprotection. Furthermore, an ongoing trial: The NeoNATI trial (NCT01241019) will
evaluate neurological outcomes at 6, 12, and 18 months of life and help clarify questions
as to whether the administration of TPM in newborns with HIE potentiates the
neuroprotective effect of treatment with hypothermia. They hypothesize that the
combination treatment with moderate whole-body hypothermia associated with TPM
administration is safe and enhances the neuroprotective properties of hypothermia for the
treatment of neonatal HIE.
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Magnesium Sulfate
Magnesium Sulfate (MgSO4) has gained a lot of interest in the research
community due to its ability to alleviate excitotoxic damage in vitro by binding to the
magnesium site on N-methyl-d-aspartate (NMDA) glutamate channel [142]. Evidence
leads researchers to believe that it also reduces secondary inflammation and associated
injury [143], acts on cell membrane stabilization and inhibition of free radical production
[144], and improves cardiovascular stability [145].
MgSO4 is also known to be neuroprotective. However, controversy regarding its
efficacy in protecting the brain in term infants who may suffer encephalopathy exists.
These thoughts emerged due to the fact that the outcomes of previous studies are highly
inconsistent when it comes to neuroprotection. Differences in dose and timing of
administration were present amidst evidence of beneficial effects [90].
Robert Galinsky and colleagues showed that the effect of MgSO4 treatment
before or shortly after acute HIE at term or near-term equivalent was highly inconsistent
between studies [90]. This caused questions and concerns to arise regarding the benefits
of MgSO4 since the perinatal studies on this topic did not directly control brain or body
temperature, yet suggested beneficial effects of MgSO4. In addition, most of these rodent
studies didn’t control environmental temperatures. The studies in which the body
temperature was controlled in large animal translational models suggested lack of effect
after 2 or 3 days of recovery [146,147,148].
Tagin and colleagues also demonstrated that there is insufficient evidence to
determine if magnesium therapy given shortly after birth to newborns with HIE reduces
death or moderate-to-severe disability [91]. Currently, an ongoing phase III clinical trial
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(NCT01646619) is assessing whether the addition of a drug such as MgSO4 while
providing therapeutic hypothermia or cooling to babies who are asphyxiated at birth
provides additional benefit to the survival and outcomes compared to cooling alone.
Severe Neurodevelopmental Disability will be assessed at discharge from the hospital
and at 18–24 months of age to assess developmental delay and cerebral palsy.
There is insufficient evidence to determine if magnesium therapy given shortly
after birth to newborns with HIE reduces death or moderate to severe disability. The
improvement in short-term outcomes without significant increase in adverse effects
supports the need for further adequately powered trials to determine if there are long-term
benefits of magnesium and to confirm its safety. Mortality should be monitored closely in
all future trials involving magnesium therapy for newborns with HIE. In the current
review, the results, although statistically insignificant for mortality between the
magnesium and the control groups, showed a trend toward an increase in mortality in the
magnesium group.

Stem Cell Therapy and Neonatal HIE
Stem cell therapy represents a modern cornerstone of promising neuroprotective
and neuroregenerative treatment options that can benefit from ongoing trials, especially
in adult stroke [92]. However, in context of perinatal HIE, it has gained importance as
adjunct treatment with hypothermia in recent clinical trials to meliorate mortality and
chronic neurological disability. Several sources for stem cells include neural
stem/progenitor cells derived from fetal tissue, mesenchymal stem cells or embryonic
stem-induced pluripotent stem cells [93,94] (Figure 3).
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Figure 3. Stem Cell Transplantation in Animal Models of HIE. Summary of stem cell
transplantation studies in various animal models of HIE. Human Dental Pulp Stem Cells
(DPSCs); Hypoxic Ischemic Encephalopathy (HIE); Mononuclear Cells (MNCs);
Mesenchymal Stem Cells (MSCs); Neuronal Stem Cells (NSC); Based upon cell dose, cell
type, transplantation timing, and administration route.
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Additionally, cord blood (CB) represents a rich source of stem cells used in
several animal models of neurological diseases [93,94,95,96,149]. Autologous
transplantation of CB, collected shortly after delivery, has the advantages of minimal ex
vivo manipulation, no necessary immunosuppression, relatively easy access, and storage
properties. CB is rich in primitive stem cells, yet it contains a limited number of cell
types, mostly mononuclear cells, and showed to be not as pluripotent as embryonic stem
cells [97]. Studies analyzing the risk and benefits of autologous CB infusion in neonates
with HIE and in children with cerebral palsy show promising results [97,150,151].
Placebo-controlled clinical trials are demanded. Currently ongoing clinical trials include
the initiated trial by Cotten et al. of autologous CB infusion in term infants with HIE
(NCT00593242) [97,152].
Due to the lack of imaging diagnostic difficulties to detect HIE in premature
newborns and insufficient data, present stem cell therapy trials are restricted to full term
infants [153,154]. Further investigation is needed for developing the best strategy
considering transplantation timing, cell dosage, ex vivo modulations, way of
administration, and choice of stem cells [97]. It should be mentioned that, besides stem
cell transplantation, there is research ongoing in the field of stem cell factors. G-CSF [3],
and glial-cell derived neurotrophic factor have shown promising results [155].
As reviewed above, the complex etiology of HIE requires treatment that will act
on multiple processes [156]. There is an important unmet need to further improve the
outcome of neonatal encephalopathy in term infants. The agents mentioned in this section
either alone or in combination deserve rigorous and focused testing in order to render
better results that would allow researchers to translate the studies to clinical scenarios.
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Optimal dose, route, and duration of administration are still parameters that need to be
researched in depth in order to provide better guidance about the next step to follow. Any
favorable results might lead to new perspectives leading to reduction of cerebral damage
in asphyxiated newborns. Intensive tests are needed to provide a platform for furthering
clinical trials to better support their use in the clinical setting and answering many
questions that remain to be answered (Figure 4).
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Figure 4. Proposed Mechanisms of Current Clinical Trials. Cord blood infusions are rich
with hematopoietic stem cells and neurotrophic factors that have numerous effects such as
immunomodulation, reduction of microglia and T-lymphocyte infiltration, as well as the
potential to increase neurogenesis and an angiogenesis. It is believed that topiramate is able
to block sodium channels and high voltage-activated calcium currents after HIE. Xenon is
believed to bind at the glycine site of the NMDA receptor and inhibit its downstream
effects. Similarly magnesium sulfate also inhibits the NMDA receptor by binding to the
magnesium site of the receptor. Allopurinol is predicted to provide neuroprotection by
directly scavenging hydroxyl radicals after HIE injury.
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Central Hypothesis
Thus our central hypothesis is to evaluate the efficacy of neuroprotective
molecules in reducing apoptosis and inflammation after neonatal HIE. As well as
characterizing the mechanistic actions of neuroprotection of these molecules and how
they interact and effect HIE pathophysiology.

Significance
The significance of these projects will be to provide a basis for clinical translation
of these neuroprotective molecules. This project also has the possibility to make strides in
the intricate task of improving the rate of mortality and the global quality of care since
neonatal hypoxic ischemic encephalopathy has a tremendous effect on the surviving
neonates, their families, and society as a whole.
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Abstract
Neonatal hypoxic-ischemic encephalopathy (HIE) is an injury that often leads to
detrimental neurological deficits. Currently, there are no established therapies for HIE
and it is critical to develop treatments that provide protection after HIE. The objective of
this study was to investigate the ability of interferon beta (IFNβ) to provide
neuroprotection and reduce apoptosis after HIE. Postnatal Day 10 rat pups were subjected
to unilateral carotid artery ligation followed by 2.5 hr of exposure to hypoxia (8% O2).
Intranasal administration of human recombinant IFNβ occurred 2 hr after HIE and infarct
volume, body weight, neurobehavioral tests, histology, immunohistochemistry, brain
water content, blood–brain barrier permeability, enzyme-linked immunosorbent assay,
and Western blot were all used to evaluate various parameters. The results showed that
both IFNβ and the Type 1 interferon receptor expression decreases after HIE. Intranasal
administration of human recombinant IFNβ was able to be detected in the central nervous
system and was able to reduce brain infarction volumes and improve neurological
behavior tests 24 hr after HIE. Western blot analysis also revealed that human
recombinant IFNβ treatment stimulated Stat3 and Bcl-2 expression leading to a decrease
in cleaved caspase-3 expression after HIE. Positive Fluoro-Jade C staining also
demonstrated that IFNβ treatment was able to decrease neuronal apoptosis. Furthermore,
the beneficial effects of IFNβ treatment were reversed when a Stat3 inhibitor was applied.
Also an intraperitoneal administration of human recombinant IFNβ into the systemic
compartment was unable to confer the same protective effects as intranasal IFNβ
treatment.
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Introduction
Neonatal hypoxic-ischemic encephalopathy (HIE) is a devastating disease that
primarily causes neuronal and white matter injury. HIE has tremendous detrimental
effects on the developing brain and is among the leading causes of death among infants,
as well as the major underlying cause of seizures in term infants (Volpe, 2001; Doycheva
et al., 2013; Shetty, 2015). Although there have been major advances in modern
technology and an increased understanding of fetal and neonatal pathologies, HIE is still
a serious condition that is unresolved and causes significant mortality and longterm
morbidity (Badr Zahr and Purdy, 2006; Gill and Perez-Polo, 2008; Northington et al.,
2011; Shankaran, 2012). These adverse events in the developing brain often lead to long
lasting detrimental neurological defects later on in life such as mental retardation,
epilepsy, cerebral palsy, learning disabilities, and other neurophysiological handicaps
(Fathali et al., 2010; Li et al., 2016). Currently, there are no specific treatments to repair
the damage caused by HIE (Zhu et al., 2013; Shaikh et al., 2015). Thus, it is critically
important to develop safe and effective therapies (Ramanantsoa et al., 2013; Caltagirone
et al., 2016).
Neonatal HIE can also be characterized as an injury that occurs in the immature
brain, resulting in delayed cell death via excitotoxicity, inflammation, and oxidative
stress (Bain et al., 2013; Dixon et al., 2015). Previous studies have shown that the
newborn brain is primed to respond to various insults with the activation of apoptotic
cascades since cell death is a normal part of development in the central nervous system
(CNS). Thus, there is a high expression of pro-apoptotic proteins in the developing brain
(Northington et al., 2011). As a consequence, mitochondrial dysfunction occurs and
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ultimately signals pathways of apoptosis (Qi et al., 2015; Alhadidi et al., 2016).
Specifically, the release of cytochrome c by the mitochondria leads to activation of
caspase-9 followed by active caspase-3 between 6 and 48 hr after injury (Gill and PerezPolo, 2008). Clinically, interferon beta (IFNβ) is the primary treatment used to combat
inflammation and flare-ups in multiple sclerosis (Johnston and So, 2012; Castrop et al.,
2013). IFNβ is able to increase expression and concentration of anti-inflammatory
cytokines, while also having the effect of decreasing the expression of pro-inflammatory
agents (Kieseier, 2011). However, the neuroprotective properties and mechanisms of
IFNβ have not yet been explored following HIE. The administration of human
recombinant IFNβ as a treatment is a novel approach in neonatal HIE since it is already a
food and drug administration approved treatment for multiple sclerosis (English and Aloi,
2015). Intrastriatal injections of IFNβ have been shown to preserve the blood–brain
barrier integrity, decrease infarct size, and block the infiltration of inflammatory cells in
an adult rat model of middle cerebral artery occlusion (Veldhuis et al., 2003). These
studies indicate that IFNβ may have some anti-apoptotic and anti-inflammatory
properties in the CNS after significant damage like HIE. IFNβ specifically acts through
the Type 1 interferon receptor (IFNR) which has been shown to be expressed on
endothelial cells and leukocytes (Ross et al., 2004; Johnston and So, 2012). It has been
characterized that after IFNR activation, the Jak-Stat pathway is triggered for positive
feedback of IFNβ and activation of several other pathways that are associated with antiapoptosis (Heim, 1999; Schindler et al., 2007; Zula et al., 2011). As a result of IFNβ
binding to the receptor, one product in neurons is Stat3 (Schindler et al., 2007; Dziennis
and Alkayed, 2008; Ramgolam et al., 2011). It has been shown that Stat3 leads to the
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increased transcription of Bcl-2, which lowers the Bax/Bcl-2 ratio (Dziennis and
Alkayed, 2008). Interestingly, p53 increases after HIE injury and induces the increase of
Bax (Northington et al., 2011). This causes a high Bax/Bcl-2 ratio leading to Baxmediated mitochondrial permeabilization, which is also known to increase after HIE
(Wullner et al., 1998; Pan et al., 2012; Thornton and Hagberg, 2015). These events can
lead to the activation and cleavage of caspases, specifically caspase-9 and caspase-3
(Wullner et al., 1998; Pan et al., 2012; Thornton and Hagberg, 2015). Thus, we were able
to derive the hypothesis that intranasal delivery of human recombinant IFNβ will provide
protection through its anti-apoptotic properties after HIE.

Materials and Methods
All protocols and experiments in this study were approved by the Institutional
Animal Care and Use Committee of Loma Linda University. All animals were handled in
accordance with the National Institute of Health Guide for the Care and Use of
Laboratory Animals.

Neonatal Hypoxic Ischemic Encephalopathy Animal Model
A modified Rice-Vannucci model was used as previously described in our past
publications (Fathali et al., 2013; Drunalini Perera et al., 2014; Charles et al., 2015).
Postnatal Day 10 Sprague-Dawley rat pups purchased from Harlan Laboratories
(Livermore, CA) were anesthetized and underwent a unilateral right common carotid
artery ligation using a 5-0 surgical silk suture. After a recovery period of 1 hr, the rat
pups were placed in a submerged 37 hypoxia chamber (8% O2) for 2.5 hr. The flow rate
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of the gas 93.82 mL/min for the first 1.25 hr and was 77.30 mL/min for the remaining
1.25 hr. Sham animals also underwent anesthesia and exposure of the carotid artery;
however, the artery was not ligated.

Postsurgical Care
After the surgeries, the rat pups were returned to their mothers. The rat pups were
monitored closely for bleeding, swelling, pain, and distress. The monitoring occurred
every 20 min for the first 2 hr, at 6 hr, and then once daily until sacrifice.

Drug Administration
Intranasal administration of IFNβ (0.03 mg/kg, 0.3 mg/kg, and 1.0 mg/kg) was
applied 2 hr after HIE in the treatment group. The best dose (0.3 mg/kg) was chosen and
administered every 24 hr until the 72-hr time point and then was 2 ASN Neuro used
throughout the duration of the study. A specific Stat3 inhibitor, WP1066 (0.5 mg/kg),
was applied via intraperitoneal injection 1 hr before HIE in combination with IFNβ
treatment. In addition, one group of animals received 0.3 mg/kg IFNβ treatment via
intraperitoneal injection. The vehicle used to dissolve the IFNβ tablets was deionized
water which was administered to the sham and vehicle groups. Human recombinant IFNβ
(Avonex) was purchased from the Loma Linda University Medical Center Pharmacy
(Loma Linda, CA), and WP1066 was obtained from Abcam (Cambridge, MA).

Intranasal Administration
Intranasal administration was performed as previously described (Topkoru et al.,
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2013; Zhang et al., 2015). Rat pups were anesthetized with isoflurane and placed on their
backs in an anesthesia chamber. Underneath the anesthesia chamber, a heating pad was
used to maintain the temperature. A rolled pad was placed under the necks of the rat pups
to keep the heads stable. After the treatment, the rat pups were monitored until they were
fully conscious and exhibited normal breathing.

2, 3, 5-Triphenyltetrazolium Chloride Monohydrate Staining

At the 24- and 72-hr time points, the rat pups were anesthetized and perfused
transcardially with phosphate-buffered saline (PBS). The brains were removed, sectioned
into 2 mm slices, and immersed into a 2% 2, 3, 5-Triphenyltetrazolium Chloride
Monohydrate (TTC) solution at 37C for 5 min as routinely performed (Chen, Burris, et
al., 2011; Dock et al., 2015). The samples were then rinsed with PBS and stored in a 10%
formaldehyde solution or underwent preparation for Western blot to be utilized in the
protein expression evaluation groups as previously described (Kramer et al., 2010). The
infarct volume was traced and analyzed with Image J Software.

Western Blot
The Western blot experiments were executed as routinely performed (Zheng et
al., 2015; Sherchan et al., 2016). Rat pups were euthanized under isoflurane followed by
the preparation of brain tissue samples. Tissues samples were created by collecting and
snap freezing the brain hemispheres with liquid nitrogen followed by storage at 80C.
Prior to the Western blot sample preparation, these samples were stained with TTC since
they are shared with the infarct evaluation groups. Cytosolic fractionation extracts were
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obtained from the brain samples. Denatured protein extract (50 mg) was electrophoresed
and transferred to a nitrocellulose membrane and probed with antibodies. The following
primary antibodies were used: Interferon beta-receptor (1:500; Santa Cruz
Biotechnology), IFNβ (1:500; Santa Cruz Biotechnology), Stat-3 (1:500; Abcam), Bcl-2
(1:1000; Cell Signaling), and cleaved caspase 3 (1:500; Cell Signaling). The membranes
were then incubated with the appropriate secondary antibodies (Santa Cruz
Biotechnology and Thermo Fisher). The optical densities of the bands were visualized
using ECL Plus (GE Healthcare Life Sciences) or Li-Cor fluorescence technology and
were analyzed with Image J Software (National Institute of Health).

Enzyme-Linked Immunosorbent Assay (ELISA) Assay
Rat pups were euthanized under isoflurane anesthesia, and the brain hemispheres
were collected, snap frozen in liquid nitrogen, and stored at 80C. Human recombinant
IFNβ from the cytosolic fractionation extracts was then detected using a commercial
ELISA kit (Thermo Scientific).

Histology and Immunohistochemistry
Immunohistochemistry was conducted as routinely executed (Chen, Zhang, et al.,
2015; Huang et al., 2015). The rat pups were perfused under anesthesia with PBS
followed by 4% formaldehyde. The brains were removed for postfixation in formalin.
The paraffin-embedded brains were then sectioned into 10 mm slices via cryostat. The
brain slices were then evaluated with immunohistochemistry and a Fluoro-Jade C
staining kit (Biosensis). The specific cellular marker antibody used was NeuN (1:100;
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Abcam). The brain slices were then incubated with the appropriate fluorescent secondary
antibodies (Jackson ImmunoResearch). The brain slices were then visualized with a
fluorescent microscope (Olympus BX51 and Keyence BZ-9000) under 20x, 40x, and 60x
magnifications with an aperture of 0.75, 0.95, and 0.95, respectively.

Short-term Neurobehavioral Tests
Both the righting reflex test and the geotactic reflex test were performed as
previously described (Zhang et al., 2013; Yuan et al., 2014). Both short-term
neurobehavioral tests were conducted at the 24-hour time point and continued to the 72hour time point after HIE.
Righting Reflex Test: The righting reflex test was performed by placing the pup in a supine
position on a table surface and recorded the amount of time for the animal to reach a prone
position, where all four paws are against the surface of the table.
Geotactic Reflex Test: The geotactic reflex test was performed by placing the rat pups in a
downward orientation on a 45-degree incline. The amount of time for the pup to recognize
its position on an incline, make a full 180-degree turn, and face the top of the incline was
recorded.

Brain Water Content
Brain water content was performed as previously conducted (Chen et al., 2009;
Li, Tao, et al., 2015). The rat pups were placed under isoflurane anesthesia and were
decapitated 24 hr after injury, and the brain hemispheres were quickly separated and
removed. All tissue samples were weighed using an analytical microbalance in order to
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obtain the wet weight. The samples were then dried at 100C for 24 hr before determining
the dry weight. Brain water content (%) was calculated as (wet weight dry weight)/wet
weight x 100.

Evan’s Blue Dye Extravasation Assay
Evan’s Blue dye extravasation was executed as previously described (Li,
McBride, et al., 2015; Merali et al., 2015; Dixon et al., 2016; Zhang et al., 2016). Evan’s
Blue dye was administered via intraperitoneal injection and allowed to circulate 6 hr
before the 24-hr time point to measure blood–brain barrier permeability. At the 24-hr
time point, the rat pups were sacrificed under anesthesia and perfused with PBS. The
brain hemispheres were then collected and homogenized in a 3:1 ratio of 50%
trichloroacetic acid to brain tissue mass. The supernatant was then analyzed at 620 nm by
spectrophotometry.

Statistical Analysis
T-test comparisons, one-way analysis of variance, Newman-Keuls multiple
comparison test, and Tukey’s post hoc analysis were performed in GraphPad Prism.

Results
Expression of IFNβ and IFNR in the CNS After HIE
IFNR expression decreases shortly after HIE insult and is also significantly
different from the naı¨ve control group after 24 hr and 72 hr (Figure 1(a)). IFNβ
significantly decreases after HIE at the 72-hr time point when compared with the naı¨ve
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control group (Figure 1(b)). There are no significant differences in protein expression 0 to
72 hr after HIE for both IFNβ and IFNR (IFNβ: N ¼ 3 rats per group; IFNR: N ¼ 4 rats
per group). Significance determined based on comparison to the naı¨ve control group (*p
< .05) as calculated by student’s T test.
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Figure 5: Endogenous Type 1 interferon receptor and interferon beta expression in the
injured hemisphere of the neonatal central nervous system. (a) Western blot analysis of the
injured brain hemisphere illustrates that IFNR expression decreased after 24 hr in the
central nervous system. (b) Western blot analysis of the injured brain hemisphere
demonstrates that IFNβ protein expression decreases at 72 hr after injury. Significance
determined based on comparison to the naïve control group (*p < .05) as calculated by
student's T test. HIE = hypoxic-ischemic encephalopathy; IFNβ = interferon beta.
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Exogenous IFNβ Reaches the CNS After Intranasal Administration
A time course of a single dose of human recombinant IFNβ intranasal
administration was performed. Intranasal IFNβ 0.3 µg/kg (N = 6 rats per group)
significantly increased 1 hr after the initial administration, and peak concentrations were
observed at the 12-hr time point. IFNβ began to decline after 24 hr; however, it was still
significantly higher than the control group (Figure 2(a)). Significance determined based
on comparisons to the naïve control group and the IN-1H group (*p < .05 vs. Naive;
#p < .05 vs. IN-1H) as calculated by the Newman-Keuls multiple comparison test.
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Figure 6: Intranasal administration of human recombinant interferon beta after 24 hr in the
central nervous system. (a) A time course of exogenous IFNβ in the injured right
hemisphere of the central nervous system after intranasal administration using an ELISA
assay. Significance determined based on comparisons to the naïve control group and the
IN-1H group (*p < .05 vs. Naive; #p < .05 vs. IN-1H) as calculated by the Newman-Keuls
multiple comparison test.
(b) Illustrates the effects of IFNβ intranasal treatment with TTC staining of 2 mm brain
slices 24 hr after neonatal hypoxic-ischemic encephalopathy. (c) Displays that intranasal
administration 0.3 µg and 1.0 µg IFNβ decreases infarct size 24 hr after injury.
Intraperitoneal administration of IFNβ did not reduce brain infarct volume. The effect of
intranasal IFNβ was reversed when coadministered with a Stat3 inhibitor (WP1066).
Significance determined based on comparisons to the HIE+Vehicle and HIE+0.03 µg IFNβ
groups (*p < .05 vs. HIE+Vehicle; #p < .05 vs. HIE+0.03 µg IFNβ) as calculated by
Tukey's test. HIE = hypoxic-ischemic encephalopathy; IFNβ = interferon beta.

66

Intranasal Administration of IFNβ Decreased Infarct Volume 24 hr after HIE
Intranasal IFNβ medium, HIE + 0.3 µg IFNβ (N = 10 rats per group) and high
dose HIE + 1.0 µg IFNβ (N = 6 rats per group) treatments were administered at 2 hr
following HIE. Both doses were able to decrease infarct volumes after 24 hr when
compared with the other control groups (*p < .05 vs. HIE + Vehicle; #p < .05 vs.
HIE + 0.03 µg IFNβ; Figure 2(b) and (c)). The low dose group, HIE + 0.03 µg IFNβ
(N = 6 rats per group), had no effect on infarct volume when compared with the
HIE + Vehicle group after 24 hr. Significance determined based on comparisons to the
HIE + Vehicle and HIE + 0.03 µg IFNβ groups (*p < .05 vs. HIE + Vehicle; #p < .05 vs.
HIE + 0.03 µg IFNβ) as calculated by Tukey's test.

Intraperitoneal Administration of IFNβ as well as Cotreatment of a Stat3 Inhibitor and
Intranasal IFNβ Fails to Reduce Infarct Volumes 24 hr After HIE
Intraperitoneal injection of IFNβ (0.3 µg) was ineffective in reducing infarct
volume 24 hr after injury (N = 4 rats per group). Also the protective effects of intranasal
administration of IFNβ were diminished when WP1066 (0.5 µg/kg), a Stat3 inhibitor,
was administered in combination with IFNβ treatment at 24 hr post injury. The
HIE + WP1066 + 0.3 µg IFNβ group (N = 5 rats per group) was not significantly different
from the HIE + Vehicle group (Figure 2(b) and (c)).

Intranasal Administration of IFNβ Has no Effect on Brain Water Content and Blood–
Brain Permeability at 24 hr after HIE
Figure 3(a) shows the trend that IFNβ treatment can reduce brain water content at
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the 24-hr time point (N = 7 per group). Brain water content in the injured right
hemisphere was significantly increased in both the HIE + Vehicle and HIE + IFNβ groups
when compared with sham controls. Significance determined based on comparisons to
the Sham group (*p < .05 vs. Sham) as calculated by Tukey's test. This indicates that at
24 hr, IFNβ treatment may not play a strong role in reducing brain edema but plays a
more anti-apoptotic role. Similarly, Figure 3(b) also shows the trend that IFNβ treatment
may decrease blood–brain barrier permeability (N = 7 per group). No significance was
determined as calculated by Tukey's test.
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Figure 7: The effects of intranasal administration of human recombinant interferon beta on
brain water content and blood barrier permeability after 24 hr after hypoxic-ischemic
encephalopathy. (a) Displays the brain water content of each hemisphere of the brain 24 hr
after hypoxic-ischemic encephalopathy, indicating brain edema in the injured right
hemisphere. Significance determined based on comparisons to the Sham group (*p < .05
vs. Sham) as calculated by Tukey's test. (b) The amount of Evan's Blue extravasation in
the hemispheres of the central nervous system after 24 hr after hypoxic-ischemic
encephalopathy. No significance was determined as calculated by Tukey's test.
HIE = hypoxic-ischemic encephalopathy; IFNβ = interferon beta.
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Intranasal Administration of IFNβ Decreases Infarct Volume and Improves ShortTerm Neurobehavioral 72 hr after HIE
Daily intranasal administration of IFNβ 0.3 µg treatment (N = 7 rats per group)
also significantly reduced infarct volume when compared with the HIE + Vehicle group
(N = 7 rats per group) at the 72-hr time point as well (Figure 4(a) and (b)). Significance
determined based on comparisons to the HIE + Vehicle group (*p < .05 vs.
HIE + Vehicle) as calculated by student's T test. The daily administration of 0.3 µg IFNβ
treatment was able to improve weight loss after injury (Figure 4(c) and (d)). At the 24-hr
time point, the HIE + Vehicle group lost a significant amount of weight when compared
with the Sham group. The HIE + 0.3 µg IFNβ was not significantly different from the
Sham group (*p < .05 vs. Sham; Figure 4(c) and (d)). At the 48-hr time period, both the
IFNβ treatment and Vehicle were significantly different from the Sham group (#p < .05
vs. Sham). Significance determined based on comparisons to the Sham 24-hr group and
the Sham 48-hr group (*p < .05 vs. Sham- 24 hr; #p < .05 vs. Sham- 48 hr) as calculated
by Tukey's test. Also at the 24-hr time point, the decrease in weight loss effect of IFNβ
treatment was reversed in the WP1066 + 0.3 µg IFNβ (N = 5 per group). Significance
determined based on comparisons to the Sham and 0.3 µg IFNβ (*p < .05 vs. Sham;
#p < .05 vs. 0.3 µg IFNβ) as calculated by Tukey's test.
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Figure 8: The effects of daily interferon beta administration after 72 hr. (a) Illustrates TTC
staining of 2 mm brain slices 72 hr after hypoxic-ischemic encephalopathy. (b) Displays
that intranasal 0.3 µg IFNβ decreases infarct size 72 hr after injury. Significance
determined based on comparisons to the HIE+Vehicle group (*p < .05 vs. HIE+Vehicle)
as calculated by student's T test. (c) A time course of changes in weight after hypoxicischemic encephalopathy. Significance determined based on comparisons to the Sham 24hr group and the Sham 48-hr group (*p < .05 vs. Sham- 24 hr; #p < .05 vs. Sham- 48 hr) as
calculated by Tukey's test. (d) The effects of IFNβ treatment on weight at 24 hr.
Significance determined based on comparisons to the Sham and 0.3 µg IFNβ (*p < .05 vs.
Sham; #p < .05 vs. 0.3 µg IFNβ) as calculated by Tukey's test. HIE = hypoxic-ischemic
encephalopathy; IFNβ = interferon beta.
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Figure 5 displays data acquired from short-term neurobehavioral tests up to the 72-hr
time point. The righting reflex test, a motor functioning test, shows that the
HIE + Vehicle group (N = 5 rats per group) required a significantly longer time to correct
their positioning when compared with the Sham groups (N = 7 rats per group) indicating
physical dysfunction at 24 hr. The HIE + Vehicle was also significantly increased at the
72-hr time point as well. Interferon treatment was able to decrease righting reflex time
and was not significantly different from the Sham group. The protective effect of IFNβ
was diminished in the HIE + WP1066 + 0.3 µg IFNβ group (N = 5 rats per group; Figure
5(c)). Significance determined based on comparisons to the Sham group (*p < .05 vs.
Sham) as calculated by Tukey's test. The geotactic reflex test illustrates similar results to
the righting reflex test (Figure 5(b)). Animals that received IFNβ intranasal treatments
were able to recognize that they were on an inclined surface and turned 180° faster, when
compared with the vehicle group. Furthermore, the effects of IFNβ were reversed, when
WP1066 was used in combination with IFNβ treatment as well (N = 5 rats per group;
*p < .05 vs. Sham; #p < .05 vs. Vehicle; Figure 5(d)). Significance determined based on
compare sons to the Sham and Vehicle groups (*p < .05 vs. Sham; #p < .05 vs. Vehicle)
as calculated by Tukey's test.
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Figure 9: Short-term neurobehavioral tests after hypoxic-ischemic encephalopathy. (a) A
time course of righting reflex behavior times after hypoxic-ischemic encephalopathy. (b)
A time course of geotactic neurobehavior times after hypoxic-ischemic encephalopathy
after 72 hr. (c) Intranasal treatment of 0.3 µg IFNβ improved righting reflex times at the
24-hr time point. Significance determined based on comparisons to the Sham group
(*p < .05 vs. Sham) as calculated by Tukey's test. (d) Intranasal treatment of 0.3 µg IFNβ
improved geotactic reflex times at the 24-hr time point. Significance determined based on
comparisons to the Sham and Vehicle groups (*p < .05 vs. Sham; #p < .05 vs. Vehicle) as
calculated by Tukey's test. HIE = hypoxic-ischemic encephalopathy.
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Intranasal Administration of IFNβ Increases Anti-Apoptotic Proteins and Decreases
Fluoro-Jade Positive Neurons
Intranasal IFNβ significantly increased expression of anti-apoptotic proteins and
decreased neuronal cell death (Figures 6 and 7). P-STAT3 expression was increased in
the HIE + 0.3 µg IFNβ group when compared with the HIE + Vehicle group 24 hr post
injury. Also P-STAT3 expression was significantly decreased after inhibition with
WP1066 (N = 5 per group; Figure 6(b)). Significance determined based on comparisons
to the HIE + Vehicle, HIE + 0.3 µg IFNβ, and Sham groups (*p < .05 vs. HIE + Vehicle;
#p < .05 vs. HIE + 0.3 µg IFNβ; (p < .05 vs. Sham) as calculated by Tukey's test. Bcl-2
expression was significantly decreased after HIE. Intranasal IFNβ treatment and IFNβ
treatment in combination with STAT3 inhibition were able to increase Bcl-2 expression
after HIE when compared with the vehicle (Figure 6(c)). Significance determined based
on comparisons to the Sham and HIE + Vehicle groups (*p < .05 vs. Sham; #p < .05 vs.
HIE + Vehicle) as calculated by Tukey's test. Cleaved caspase-3 expression was
significantly increased in the HIE + Vehicle and HIE + WP1066 + 0.3 µg IFNβ groups.
Cleaved caspase-3 expression was lower in the HIE + 0.3 µg IFNβ after 24 hr and not
significantly different from any of the other groups (p = .0633 vs. Sham; N = 5 rats per
group for all groups; Figure 6(d)). Significance determined based on comparisons to the
Sham group (*p < .05 vs. Sham) as calculated by Tukey's test.
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Figure 10: Expression of anti-apoptotic proteins involved with interferon beta treatment
24 hr after hypoxic-ischemic encephalopathy. (a) Representative Western blot images of
P-STAT3, Bcl-2, and cleaved caspase-3 (CC3) expression in the injured right hemisphere
of the brain 24 hr after hypoxic-ischemic encephalopathy. (b) Western blot analysis of PSTAT3 expression in the injured right brain hemisphere 24 hr after hypoxic-ischemic
encephalopathy. Significance determined based on comparisons to the HIE+Vehicle,
HIE+0.3 µg IFNβ, and Sham groups (*p < .05 vs. HIE+Vehicle; #p < .05 vs. HIE+0.3 µg
IFNβ; (p < .05 vs. Sham) as calculated by Tukey's test. (c) Western blot analysis of BCL2 expression in the injured right brain hemisphere 24 hr after injury. Significance
determined based on comparisons to the Sham and HIE+Vehicle groups (*p < .05 vs.
Sham; #p < .05 vs. HIE+Vehicle) as calculated by Tukey's test. (d) Western blot analysis
of cleaved caspase-3 expression in the injured right brain hemisphere at 24 hr after injury.
Significance determined based on comparisons to the Sham group (*p < .05 vs. Sham) as
calculated by Tukey's test. HIE = hypoxic-ischemic encephalopathy.
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Figure 11: Illustrates positive Fluoro-Jade C expression in the central nervous system after
24 hr after injury. (a) Shows positive staining in the hippocampal region of the brain in the
sham group at the 24-hr time point after utilizing immunohistochemistry and a Fluoro-Jade
C kit. (b) Illustrates positive Fluoro-Jade C staining in the hippocampal region of the brain
in the vehicle group after 24 hr using immunohistochemistry and a Fluoro-Jade C kit. (c)
Immunohistochemistry and Fluoro-Jade C staining kit revealed positive Fluoro-Jade C
staining in the hippocampal region of the brain after intranasal administration of 0.3 µg
IFNβ. IFNβ = interferon beta.
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After HIE, there was more positive Fluoro-Jade C expression in the hippocampal region
in the HIE + Vehicle group. Intranasal IFNβ treatment decreased the expression of
positive Fluoro-Jade C expression, the Sham group also had a decreased expression as
well (Figure 7).

Discussion
There are a few studies evaluating the effects of IFNβ treatment after ischemic
stroke (Veldhuis et al., 2003; Marsh et al., 2009; Kuo et al., 2016). One of the earliest
studies explored IFNβ treatment after middle cerebral artery occlusion in a rabbit model
and found that IFNβ was neuroprotective and decreased infarct volumes (Liu et al.,
2002). However, another study reported that IFNβ treatment failed following middle
cerebral artery occlusion in a rat model. The authors of this study suggested that IFNβ
treatment was unable to reach the affected tissues in the CNS since the blood–brain
barrier was not sufficiently disrupted in their model (Maier et al., 2006).
Thus in our study, we chose intranasal administration of IFNβ treatment since it is
clinically viable and noninvasive (Brown and Liu, 2014). Also intranasal delivery of
IFNβ has previously been shown to effectively bypass the blood–brain barrier and
directly target the CNS in a rat model of multiple sclerosis (Ross et al., 2004). To our
knowledge, this is the first study to explore the effects of IFNβ treatment after neonatal
HIE as well as the first to explore anti-apoptotic mechanisms involved with IFNβ in this
model.
In the present study, we observed that overall expression of both the IFNR and
IFNβ decreases in the CNS after neonatal HIE. We also found that intranasal IFNβ
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treatment was able to decrease infarction volumes after 24 hr and 72 hr, improve shortterm neurobehavior at those time points, as well as improve postsurgery weight gain.
Intranasal IFNβ treatment also had an anti-apoptotic effect of increasing Stat3 and Bcl-2
expression in addition to decreasing the expression of cleaved caspase-3 and neuronal
degeneration. Moreover, pharmacological inhibition of Stat3 expression with the specific
Stat3 inhibitor, WP1066, was able to reverse the protective effects of IFNβ that we
observed. Pharmacological inhibition of Stat3 reversed protective effects of decreased
infarction volumes and short-term behavior after HIE when applied in combination with
intranasal IFNβ treatment.
The importance of Stat3 expression after stroke and neonatal HIE has been
controversial. Our results show that IFNβ treatment increased Stat3 activation, the
downstream product, after HIE. It has been previously suggested that treatments with the
ability to activate Stat3 expression have been found to improve behavioral functions and
decrease cell death after stroke (Raible et al., 2014). Our previous study demonstrating
the effects of granulocyte-colony stimulating factor (G-CSF) in an experimental model of
HIE observed that Stat3 was among some of the proteins contributing to anti-apoptosis in
the study (Yata et al., 2007). Kinouchi et al. (2012) also found that activation of Stat3 in
the peri-infarct region was associated with inhibition of apoptosis in a model of middle
cerebral artery occlusion. Conversely, Hristova et al. observed that complete knockout of
Stat3 in neurons and astrocytes after neonatal HIE in mice reduced brain damage and
attenuated apoptosis by decreasing microglial activation, astroglial activation, and
reactive astrogliosis. Interestingly, the same study also found that successful preinsult and
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postinsult pharmacological inhibition of Stat3 with WP1066 resulted in a weak response
that did not reduce brain tissue loss (Hristova et al., 2016).
Similarly, we observed that pharmacological Stat3 inhibition in combination with IFNβ
treatment also did not yield improvement to brain infarction volume. Also Stat3
inhibition in concert with IFNβ treatment did not improve short-term neurobehavior or
increases in anti-apoptotic protein expression suggesting that the beneficial effects of
IFNβ treatment are mediated through Stat3 expression.
Our previous publications have demonstrated that hypoxic ischemic injury in the
CNS induces the expression of Bax leading to apoptotic cell death (Charles et al., 2012).
We have also previously demonstrated that the Bcl-2 is significantly decreased 24 hr after
HIE and that increases in its expression leads to decreases in cleaved caspase-3 and
neuronal cell death (Charles et al., 2012; Li, Klebe, et al., 2015). Other studies have also
shown that increases in Bcl-2 lead to a decrease in neuronal apoptosis as well (Hu et al.,
2014; Chen, Xu, et al., 2015). Similarly, our results show that Bcl-2 is decreased 24 hr
after HIE and that intranasal IFNβ is able to increase Bcl-2 expression after injury
contributing to neuronal survival. We believe that this effect is mediated by an increase in
Bcl-2 which was induced by Stat3 activation via IFNβ treatment. Bcl-2 expression was
also elevated in the Stat3 inhibition group as well. Since we observed the whole cellular
expression of Bcl-2 in the injured hemisphere it is possible that other cell types
contributed to the elevation of Bcl-2 in response to Stat3 inhibition.
It has been previously shown that cleaved caspase-3 expression increases after HIE and
peaks at the 24-hr time point contributing to neuronal apoptosis (Wang et al., 2001;
Askalan et al., 2015). Increased expression of positive Fluoro-Jade C staining has been
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observed before after 24 hr after HIE (Aggarwal et al., 2014). Our studies also showed
that cleaved caspase-3 expression increased after 24 hr in the HIE + Vehicle group and
that there is increased positive staining of Fluoro-Jade C expression as well. In our
studies, intranasal IFNβ treatment was able to decrease cleaved caspase-3 expression and
neuronal apoptosis after 24 hr after injury.
Following HIE, sensorimotor functions and reflex maturation are severely
affected as well (Sanches et al., 2012; Alexander et al., 2014). Our findings show that
IFNβ treatment was able to improve sensorimotor deficits and reflex maturation delays
since there was an improvement in the performance on the righting reflex and geotactic
reflex short-term neurobehavioral tests after HIE. Body weights of the rat pups can also
be used as an indicator of general health after HIE (Chen, Ma, et al., 2011), thus we
recorded the weights of the rat pups each day after injury. Normally after HIE, there is a
significant amount of loss in weight after injury as evidenced by the literature and our
previous studies (Carty et al., 2008; Fathali et al., 2013). In the present study, our data
show that IFNβ treatment was able to provide an improvement of general health since
weight loss after injury was significantly reduced.
Our results also demonstrated that IFNβ treatment had no effect on brain edema
and blood–brain barrier permeability at the 24-hr time point. This result helped us focus
our attention upon the anti-apoptotic effects that IFNβ treatment had on neurons since we
observed decreases in the infarction volume at the 24-hr time point. Our results also
showed that there was no detectable blood–brain barrier disruption at 24 hr after neonatal
HIE injury as the vehicle group is not significantly different from the sham control group.
Previous studies of neonatal HIE from our laboratory and the literature confirm and
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report similar findings that detectable disruptions of the blood–brain barrier occur at 48 hr
after neonatal stroke in the rat pup model (Fernandez-Lopez et al., 2012; Li, McBride, et
al., 2015).
In conclusion, we report that intranasal administration of human recombinant
IFNβ treatment was able to attenuate neuronal apoptosis via the Jak1/Stat3/Bcl-2
pathway after neonatal HIE (Figure 8). We determined that intranasal human
recombinant IFNβ treatment induces Stat3 activation and leads to increased expression of
Bcl-2 which led to a decrease in cleaved caspase-3 expression and neuronal degeneration.
IFNβ treatment has the potential to become a new therapeutic strategy after HIE, however
more translational studies are still needed. Future studies should also explore potential
anti-inflammatory mechanisms after IFNβ administration after HIE.

Summary
Intranasal treatment with human recombinant IFNβ reduces brain injury and
improves neurological functions after hypoxic-ischemic injury. These findings suggest
that IFNβ could be a potential therapy for neonatal hypoxic-ischemic encephalopathy in
the future.
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Figure 12: A visual schematic. In our experiments human recombinant interferon beta
(IFN-β) administered through the intranasal route was able to bind and activate the Type 1
interferon receptor (IFNR). Activation of INFR leads to increases of P-Stat3 activation and
transcription of Bcl-2, which increases the Bcl-2/Bax ratio. This eventually leads to the
decreased expression of caspase 3 and ultimately decreases in neuronal cell death.
IFNβ = interferon beta; IFNR = Type 1 interferon receptor.
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Abstract
Isoflurane is a volatile anesthetic that is widely used clinically as an inhalational
anesthetic. In recent years, several studies have indicated that isoflurane has
neuroprotective properties. This has led to the beneficial effects of isoflurane being
analyzed in both cell culture and animal models, including various models of brain
injury. Neonatal hypoxia ischemia may be characterized as injury that occurs in the
immature brain, resulting in delayed cell death via excitotoxicity and oxidative stress.
These adverse events in the developing brain often lead to detrimental neurological
defects in the future. Currently, there are no well-established effective therapies for
neonatal hypoxia ischemia. In line with this, isoflurane, which displays neuroprotective
properties in several paradigms and has been shown to improve neurological deficits
caused by brain injuries, has the capability to be an extremely relevant clinical therapy
for the resolution of deficits concomitant with neonatal hypoxic ischemic brain injuries.
This review will therefore seek to explore and analyze the current information on
isoflurane, looking at general isoflurane anesthetic properties, and the protection it
confers in different animal models, focusing particularly on neuroprotection as shown in
studies with neonatal hypoxic ischemic brain injury.
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Isoflurane and Other Volatile Anesthetics
Isoflurane is a volatile anesthetic that has been in clinical practice for several
decades. Volatile anesthetics are also known as inhalational anesthetics and, apart from
isoflurane, also include sevoflurane, desflurane, halothane, and enflurane. Of the five
major volatile anesthetics, isoflurane, sevoflurane, and desflurane are most commonly
used today. Halothane and enflurane are not used widely due to undesirable side effects1.
The volatile anesthetics all differ in potency, adverse effects, and cost, and are used
extensively during surgery in human neonates and during neonatal animal research.
Moreover, volatile anesthetics are employed in about 80% of the surgeries in the United
States that are performed under general anesthesia2. Volatile anesthetics have been
reported to produce their effects by a number of mechanisms, including antagonism of
ionic channels, activation of glycine and γ-aminobutyric acid (GABA) receptors, and
alteration of the function and activity of other cellular proteins, as well as through
utilizing high lipid solubility characteristics 3,4. Isoflurane (2-chloro-2-(difluoromethoxy)1,1,1-trifluoro-ethane, CHF2-O-CHCl-CF3), has been shown to be more potent than
several other anesthetics. It is much more widely used in comparison to the other
inhalational fluorinated inhalational anesthetics5. Isoflurane was discovered in 1965 by
Dr. Ross Terrell and associates in their quest for a better inhaled anesthetic than was
available at the time and was the 469th compound found, following enflurane and
halothane5. Isoflurane has a minimum alveolar concentration (MAC) of 1.15%, and
blood/gas partition coefficient of 1.4, lower than that of most other inhaled anesthetics6.
Also, isoflurane is very stable and is resistant to biodegradation3. These properties of
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isoflurane allow it to rapidly induce unconsciousness and also to be quickly eliminated
from circulation.

Isoflurane is Protective in Various Animal Models
Isoflurane has been studied in animal models of various diseased states, such as
Lipopolysaccharide (LPS)-induced Acute Inflammation of the Lung7, Acute Lung
Injury8, glucose-induced oxidative stress9, renal ischemia/reperfusion injury 10,11, cardiac
injury12, etc. In these models, it is shown to provide protection from injury and improve
various negative functional outcomes. The protective effects of isoflurane in these models
are reported to occur through the activation of several pathways, and are briefly outlined
in Table 1.
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Table 3. Isoflurane shows protection in various animal models
Animal Model
LPS-Induced Actute Lung
Inflammation (Rat)
T/HS-induced ALI
Renal Ischemia/ Reperfusion
Injury
Cardiac Injury

High Glucose-induced Oxidative
Stress in Isolated Human Artery
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Subarachnoid Hemorrhage

Middle Cerebral Artery
Occlusion

Intracerebral Hemorrhage
Traumatic Brain Injury
Neonatal Hypoxic Ischemic
Brain Injury

Isoflurane Protection
General Models
Inhibited ROS burst, NF-κB activation,
and pro-inflammatory cytokines

Source

Inhibited platelets through the ADP
pathway
Reduced renal dysfunction and tubular
necrosis via the SK/S1P pathway
Attenuated the release of LDH and CKMB, and reduced infarct size via
PKCε/ALDH2 pathway
Preserved vascular function by restoring
ATP-sensitive K+ channel function

Harr, N. et.al. 2012

Stroke Models
Prevented post SAH neuronal apoptosis
and BBB disruption in ipsilateral
hemisphere through S1P pathway
Improved neurological outcome, and
reduced inflammatory cytokine
production via attenuation of NF-κB
activation
Reduced brain edema, apoptotic cell
death, and neurological deficits
Increased CA3 neuronal survival, and
improved histopathology
Reduced infarction volume, improved
neurobehavioral outcome, and increased
pAkt

Chung, I.S. et.al. 2013

Kim, M. et.al.2007; Lee,
H.T. et.al. 2004
Lang, X. et.al. 2013

Kinoshita, H. et.al. 2012

Altay, O. et.al. 2012

Li, H. et.al. 2013

Khatibi, N. H. et.al. 2011
Statler, K.D. et.al. 2006
Zhou, Y. et.al. 2010

In particular, isoflurane shows neuroprotection in several stroke models including
subarachnoid hemorrhage (SAH)13, middle cerebral artery occlusion (MCAO)14,15 ,
intracerebral hemorrhage 16, traumatic brain injury17, and Neonatal Hypoxic Ischemic
Brain Injury (HI)18 (Table 1). For this review, the main focus will be on the
neuroprotection of isoflurane as studied in neonatal HI, its possible mechanisms of
action, and what direction this could be leading us in terms of clinical applications of
isoflurane treatment.

Neonatal Hypoxia-Ischemia
Neonatal Hypoxia Ischemia is a major cause of mortality and neurological deficits
such as cerebral palsy, mental retardation, and epilepsy in the perinatal period19,20.
Several factors have been implicated in the pathophysiology of HI, including
inflammatory mediators, excitotoxicity, and oxidative stress21. While extensive research
has been done on this form of brain injury, there is a gap between the basic and clinical
sciences as successful treatments are still lacking. There is still a significant number of
neonates who suffer from perinatal HI and its repercussions, approximately 1 in 4000, a
figure two to three times higher than the incidence of childhood stroke22. The methods of
interventions are often limited for neonatal HI, since neuronal cell death is frequently
only delayed, although it usually appears to be prevented shortly after an assault. Thus, it
is essential that more preclinical studies be carried out to elucidate the possibility of an
effective therapy that will provide long-term neuroprotection against HI in the perinatal
period, reducing the effects seen up to adulthood. To study neonatal hypoxic ischemic
brain injury, the Rice-Vannucci model is the one that is most widely used. Induction is
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most commonly with isoflurane at 3% and occurs for 4 minutes, followed by ligation of
the right common carotid artery in rat pups. Isoflurane is continuously infused for the
duration of the surgery (typically not longer than 5 minutes) at 2.5%. The inspired
concentration of isoflurane is lowered (from 3% to 2.5%) as this compensates for the
decreased uptake due to the equilibration of isoflurane in the body following the
induction period5. The pups are then subjected to a hypoxic chamber with 8% oxygen at
37°C for 2.5 hours. Infarction volumes are calculated and other neurological assessments
are done at different time points after surgery. This method has been modified from that
described by Rice, Vannucci, and Brierly, and is most commonly done in postnatal day 7
or 10 rats23. P7 rat pups represent a human fetus at gestational age 32 to 34 weeks or a
newborn infant at this stage24, while P10 rats are similar to the older neonate approaching
adolescent stages of development or a full-term neonate25.

Neuroprotection of Isoflurane in Neonatal HI: Possible Mechanisms
The use of isoflurane as an anesthetic in the surgery for modeling neonatal HI,
along with the great variations observed in infarct sizes within and among litters,
particularly as surgery times varied has led to speculations on the effects that isoflurane
may be having on these neonates. This, among other reasons, has therefore sparked the
interest in studying whether or not isoflurane may be providing some form of
neuroprotection against ischemic injury in neonatal rat pups. As a result, several studies
have found that isoflurane, when it is administered before or after an experimental
hypoxic-ischemic insult (pre- and post-conditioning) in neonates, has the ability to reduce
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negative outcomes. Studies indicate that isoflurane acts through a number of mechanisms
that are involved with neuroprotection and an increase in neuronal viability (Figure 1).
It has been suggested that isoflurane inhibits excitotoxicity that is initiated by an
accumulation of glutamate during ischemia, resulting in a reduction in necrosis. The
antagonism of glutamate receptors by isoflurane has been shown in in vitro studies, as
well as in in vivo models where isoflurane reduced extracellular glutamate during
ischemia26. In addition, isoflurane has been shown to be a GABA receptor agonist,
providing an inhibitory effect against excitotoxicity3. Under hypoxic conditions
isoflurane was shown to be protective via its interaction with the pathways that involve
phospholipase C and the release of Ca2+ from intracellular stores. Phospholipase C
triggers the Phosphatidylinositol-3-kinase/Protein Kinase B and Mitogenactivated protein
kinase (PI3K/Akt/MAPK) pathways, which are anti-apoptotic27. Isoflurane also induced
neuroprotection by altering the phosphorylation states of players in both the calciumdependent and calcium-independent MAP kinase pathways, increasing the
phosphorylation of some of the kinases (Pyk-2, ERK, MKK-6, JNK), while decreasing
the phosphorylation of the downstream MAP kinase dependent transcription factors (p38,
pElk-1 p90 RSK, ATF-2). Phosphorylation of the MAP kinases was prevented by an
inositol triphosphate (IP3) receptor antagonist, suggesting that this phenomenon after
isoflurane preconditioning depends on the small increases in intracellular Ca2+. The study
also showed that isoflurane enabled neurons to avoid potentially toxic levels of Ca2+
increase. Moreover, there was an observed increase in the levels of Akt, an anti-apoptotic
protein, due to isoflurane preconditioning27,28. The activation of the Akt pathway was also
observed in a model of oxidative and inflammatory stress on cardiac myocytes.
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Figure 13. Proposed Mechanisms of Isoflurane Neuroprotection. Other potential
mechanisms have been explored; however, these are the most extensively addressed in this
review18,29,40,41.
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Isoflurane was shown to prevent apoptosis by activating Akt and enhancing B-cell
lymphoma-2 (Bcl-2) expression29,30. Furthermore, isoflurane was shown to protect
against oxygen glucose deprivation-induced ischemia in neuronal cultures by activating
the cell-surviving protein, hypoxia inducible factor -1α (HIF-1α) and the subsequent
increase in expression of inducible nitric oxide synthase (iNOS) mRNA. Notably, the
protection observed with isoflurane preconditioning was also dependent on the
extracellular signal-related kinase (ERK) pathway; an ERK1/2 inhibitor partially reversed
the protective effects that resulted from isoflurane administration31. The aforementioned
studies were mainly carried out in in vitro models of hypoxia, and though they may
provide clearer mechanistic pathway descriptions, they differ from the physiology seen in
intact animals. However, similar neuroprotection has been observed in vivo. In one study
done in an animal model of neonatal HI, Chen et.al, hypothesized that longer isoflurane
exposure times may be one of the underlying factors leading to the inconsistent results in
infarction volumes observed in the model. The results showed that longer surgery times,
and hence longer isoflurane exposure, resulted in decreased infarction severity in the rat
pups. Pups that had exposure times to isoflurane of 13 or 21 minutes, had significantly
less volume of infarction than those with only 5 minutes of exposure: 33.2% in the 5
minute group, versus 20.3% in the 13 minute group and 11.3% in the 21 minute group in
the 7-day old pups. This trend was also observed in the 10-day old rat pups (24.8% in the
5-minute group versus 11.9% in the 13-minute group and 9.3% in the 21-minute group)25.
By extension, this group also did experiments to elucidate the mechanism by which
isoflurane was participating in this neuroprotective role. They found that the sphingosine1- kinase/PI3K/Akt (S1P/PI3K/Akt) pathway is active in this function as administration
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of selective inhibitors of S1P (VPC23019) and PI3K (Wortmannin) completely reversed
the effects of isoflurane-induced neuroprotection. Importantly, isoflurane provided both
short and long-term neuroprotection as effects were observed up to 4 weeks after the HI
injury, when neurobehavioral tests were carried out. The effect of the S1P and PI3K
inhibitors had a long-term effect as well, reversing the improvement in neurobehavior
induced by longer exposures to isoflurane. Also, Akt phosphorylation was preserved in
the isoflurane pretreated group, and a significant reduction in cleaved caspase-3 levels
was observed. These findings confirmed the speculation of the involvement of the
S1P/PI3K/Akt pathway18. In addition, in a SAH model, isoflurane was also shown to be
neuroprotective by activating the sphingosine kinase/S1P (SK/S1P) pathway. Isoflurane
treatment attenuated the disruption of the blood-brain-barrier (BBB) that usually occurs
after SAH13. The involvement of the S1P/PI3K/Akt pathway in protection has also been
implicated by other groups in different models of ischemia. Isoflurane was found to
protect against renal dysfunction, significantly lowering plasma creatinine values and
tubular necrosis, an effect abrogated by SK and S1P receptor antagonists, providing
further evidence that their activity is essential to isoflurane-induced protection against
ischemia. Additionally, mice lacking the SK1 enzyme were not protected against injury
from ischemia10. The S1P pathway involvement in protection was seen in cardiac
ischemia reperfusion injury also as the administration of S1P, which activated the S1P
receptor, resulted in reduced infarct sizes, leukocyte recruitment and adhesion32. In
models of liver ischemia, the SK/SIP pathway was also shown to be activated. There was
a significant improvement in hepatic function in both normal and cirrhotic livers,
increased anti-inflammatory cytokine production, and downregulation of anti-apoptotic
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genes following ischemia-reperfusion injury due to the activation of S1P33. Volatile
anesthetics, including isoflurane, have been proposed to be exhibit potency as a result of
their high lipid solubility3. This theory was proposed by Meyer and Overton in 1901 and
has been used to explain the involvement of the lysophospholipid, Sphingosine-1phosphate, which results from the activation of sphingomyelin hydrolysis34.
Sphingomyelin is a lipid component of the membrane which is hydrolyzed to ceramide, a
precursor of sphingosine. Sphingosine is then converted to S1P by the enzyme
sphingosine kinase10. Spingosine kinase is involved in many different biological
processes including cell growth and cell survival35. In addition, sphingosine kinase and
S1P have been shown to upregulate the ERK/MAPK pathway, resulting in increased cell
survival36,37. A significant finding was that animals with a knockout of the SK gene could
not be protected by isoflurane treatment10,38. These studies all correlate with the Lipid
Theory which describes the potency of volatile anesthetics in relation to lipid solubility.
However, in recent years, the Protein Theory, which postulates that anesthetics act
directly on proteins rather than accumulating in membranes, has stimulated a lot of
interest3,39. Consequently, other mechanisms have been proposed on how isoflurane
confers neuroprotection. One such pathway is through the activation of inducible nitric
oxide synthases (iNOS). Zhao, et.al found that isoflurane induced an increase in nitric
oxide and suggested that this may be the mediator for the neuroprotection induced by
isoflurane. They confirmed this by the use of a nitric oxide inhibitor, aminoguanidine,
which abolished the neuroprotection conferred by isoflurane22. Isoflurane neuroprotection
was shown using a preconditioning model where isoflurane was given at 1.5% for 30
minutes 24 hours before the hypoxic insult. Neuroprotection was measured up to 7 days
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post injury. In another study by the same group, it was found that the brain loss induced
by HI was significantly attenuated up to one month following injury, when animals were
preconditioned with 1.5% isoflurane for 30 minutes 24 hours before injury. This
conclusion was made as there were no significant differences between control and
isoflurane treated groups in long-term reference memory, as well as short-term working
memory. Isoflurane also significantly improved motor coordination one month after
injury. Additionally, preconditioning with isoflurane resulted in increased Bcl-2
expression in the hippocampus40. Bcl-2 can decrease the release of cytochrome C and
mitochondrial membrane permeability caused by ischemic episodes40. Again, it was
found that the protection by isoflurane could be reversed by administration of an
inducible nitric oxide synthase inhibitor, suggesting a role for iNOS in the isofluraneinduced neuroprotection. Small increases in iNOS protein expression have been
associated with cardioprotection and neuroprotection. iNOS is believed to be an
important factor for protection since protein kinase C(PKC) and MAP kinase are both
located downstream of iNOS and are believed to provide protection41. Notably, isoflurane
was found to increase the p38 MAPK phosphorylation status after an ischemic injury and
the reduction induced by preconditioning with isoflurane was abolished by the
administration of a p38 MAPK inhibitor42. Kapinya et.al. also found that isoflurane
preconditioning resulted in an increase in iNOS in an MCAO model and suggested that
the increase in iNOS may be the means by which isoflurane reduces infarction volume
and other neurological deficits. However, they also stated that further study is needed to
identify the underlying anesthetic mechanism as the increase in iNOS was not observed
until 6 hours after the preconditioning event, while protection was seen immediately after
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preconditioning with isoflurane43. Nitric oxide is known to interact with two survival
pathways: the Ras/Raf/MEK/ERK pathway and the PI3K/Akt pathway44. Both of these
pathways are essential to neuronal survival and could therefore be the underlying
mechanism by which the isoflurane-induced increase in iNOS is protective in brain injury
models. However, there is some contradiction in this area as NO has been shown to be
both protective and toxic44. Therefore, there are still further studies that need to be done
to clarify the neuroprotection of isoflurane via an increase in iNOS. The studies described
above show a long-term neuroprotective role of the anesthetic, isoflurane. This is
significant as a large percentage of infants who suffer from neonatal HI do survive into
adulthood; however, most of them have residual motor and cognitive deficits21. However,
importantly, there have been contradictions on whether or not the neuroprotection
provided by isoflurane is long-term, or only transient. A study done by McAuliffe, et.al,
suggested that isoflurane may be useful in preventing the deficits seen long after the
neonatal injury, or at least reducing the severity. This conclusion was made from
experiments that showed that preconditioning with isoflurane improved striatal function
in adulthood. Neurobehavioral testing was also done by the use of a water maze with
adult mice that had undergone neonatal HI, and was done at 70 days old. Mice
preconditioned with isoflurane performed as well as sham in this neurobehavioral test and
this therefore provides evidence for long-term neuroprotection45. By contrast, Sasaoka,
et.al found that preconditioning with isoflurane at 2% for either 60 or 90 minutes before
the HI insult induced ischemic tolerance in the hippocampus of P7 rat pups up to 7 days
after the injury, but not at 49 days20. These results suggest that the neuroprotective effect
of isoflurane is only transient. This may be due to the rapid removal of isoflurane from
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the system as a result of small amounts of biodegradation, as stated before. It has also
been suggested that isoflurane preconditioning may simply be delaying neuronal injury,
not preventing it. This idea was proposed based on results that showed that brain
infarction in the isoflurane treated group was significantly reduced in comparison to
controls two days following ischemic injury, but this reduction was not seen 14 days after
the insult. However, isoflurane did reduce the number of necrotic cells in the penumbral
area two weeks after ischemia was induced46. This experiment was carried out in an adult
model of ischemia. Nevertheless, it still presents a significant consideration to be made
with regards to the use of isoflurane for neuroprotection clinically because the delay in
neuronal injury provided by isoflurane may provide a longer therapeutic window for
other interventions.

Future Directions
It is clear that isoflurane exhibits neuroprotective properties, and harnessing this
capability of the volatile anesthetic may be very relevant clinically. However, while
isoflurane has been shown to be beneficial in numerous cases, before it can be used as a
neuroprotective therapy for neonatal HI, several concerns have to be addressed. One such
consideration is the length of time that isoflurane is administered. Studies have shown
that isoflurane exposure for periods of 3 to 6 hours resulted in caspase activation and
neuronal death47,48, in contrast to the potent neuroprotection observed with shorter
exposure times25,40. Therefore, studies specifically aimed at establishing an optimal time
period within which there is still effective neuroprotection from isoflurane, without
causing neurotoxicity, have to be done. There are contradictory evidences in support of
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isoflurane playing a neuroprotective role, while at the same time, potentially being
neurotoxic. As discussed above, there are many animal studies that show isoflurane to be
convincingly neuroprotective. However, evidence based on clinical studies in humans is
not as strong4. And while there is not much evidence on the neurotoxicity resulting from
isoflurane anesthesia, the fact that there is any, is reason for considerations to be made in
this regard before clinical isoflurane therapy can progress substantially. Isoflurane studies
are clinically relevant and translatable because the percentage of isoflurane used
experimentally is around 1.15% to 2%, which is comparable to a MAC of 1.15% in
human adults and 1.6% in human neonates40. However, different researchers have found
the most effective dosages to be different in their models. With these discrepancies, much
more would need to be done to establish what the optimal dosage of isoflurane is that will
be mosy effective, providing maximal neuroprotection to infants. Another factor that is
very important to consider is elucidating the exact mechanism by which isoflurane
provides protection from cell death and other negative outcomes. Several different
pathways have been implicated to date. It was first postulated that isoflurane, and volatile
anesthetics by extension, were more potent the more lipid-solubility they exhibited3.
Since the membrane is composed mainly of lipids, they were thought to act through
membrane lipids. Hence, sphingosine and sphingosine kinase were suggested to be
involved. From this theory, several studies carried out in various models have shown that
isoflurane provides neuroprotection by activating this pathway, which then upregulates
the ERK/ MAPK/Akt pathway, resulting in increased cell growth and survival. However,
newer theories indicate a more protein-based mechanism of action, via several ion
channels, as well as GABA and glutamate receptors. The involvement of iNOS in
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isoflurane-mediated neuroprotection is another popular mechanism proposed and is more
in line with the Protein Theory. Notably, many of these pathways, including sphingosine1-phosphate and iNOS, exhibit protection via the activation of the ERK/MAPK/Akt
pathway. This is significant and may be the way to connect the different pathways
implicated, thereby establishing how isoflurane is protecting neurons from cell death.
Finally, neonatal HI results from several different patholophysiological manifestations.
Hence, it may be necessary to target more than one of these to provide sufficient
neuroprotection. Consequently, using isoflurane along with another intervention may be
much more effective. Moreover, with the suggestion by some studies that isoflurane is
merely delaying repercussions from ischemia, rather than preventing them, this may open
a longer therapeutic window for other interventions to be applied, and may also provide
an additive protective effect. The possibility of using isoflurane clinically is very
promising, and with the fact that it is already so widely used, addressing the current
concerns would prove very beneficial in progressing not only the field of neonatal brain
injury, but also many diseases related to hypoxia and ischemia.
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Abstract
Objective: Neonatal hypoxia occurs in approximately 60% of premature births
and is associated with a multitude of neurological disorders. While various treatments
have been developed, translating them from bench to bed- side has been limited. We
previously showed G-CSF administration was neuroprotective in a neonatal hypoxiaischemia rat pup model, leading us to hypothesize that G-CSF inactivation of GSK-3β via
the PI3K/Akt pathway may attenuate neuroinflammation and stabilize the blood–brain
barrier (BBB).
Methods: P10 Sprague–Dawley rat pups were subjected to unilateral carotid
artery ligation followed by hypoxia for 2.5 h. We assessed inflammation by measuring
expression levels of IKKβ, NF-κB, TNF-α, IL-1β, IL-10, and IL-12 as well as neutrophil
infiltration. BBB stabilization was evaluated by measuring Evans blue extravasation, and
Western blot analysis of Claudin-3, Claudin-5, ICAM-1, and VCAM-1.
Measurements and main results: First, the time course study showed that p-βcatenin/β-catenin, IKKβ, and NF-κB expression levels peaked at 48 h post-HI. The
knockdown of GSK-3β with siRNA prevented the HI-induced in- crease of p-β-catenin/βcatenin, IKKβ, and NF-κB expression levels 48 h after HI. G-CSF treatment reduced
brain water content and neuroinflammation by downregulating IKKβ, NF-κB, TNF-α, IL1β, and IL-12 and upreg- ulating IL-10, thereby reducing neutrophil infiltration.
Additionally, G-CSF stabilizes the BBB by downregulating VCAM-1 and ICAM-1, as
well as upregulating Claudins 3 and 5 in endothelial cells. G-CSFR knockdown by
siRNA and Akt inhibition by Wortmannin reversed G-CSF's neuroprotective effects.
Conclusions: We demonstrate G-CSF plays a pivotal role in attenuating
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neuroinflammation and BBB disruption following HI by inactivating GSK-3β through
the PI3K/Akt pathway.
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Introduction
Neonatal hypoxia-ischemia (HI) is an injury that occurs in less than 1% of fullterm infant births; however, the occurrence of HI is increased to approximately 60% of
premature births (Vannucci and Vannucci, 1997 and Volpe, 2001). In 20–40% of HI
cases, infants develop neurological disorders, such as mental retardation, epilepsy, and
cerebral palsy (Vannucci et al., 1999). Various experimental therapies have been
investigated for improving HI patient outcomes and quality of life, yet successful clinical
translation has been limited (Burchell et al., 2013, Koenigsberger, 2000 and Zanelli et al.,
2009). Thus, it is of the utmost importance to identify novel therapeutics with potential
for clinical translation.
Granulocyte stimulating factor (G-CSF) is a hematopoietic growth factor with
known neuroprotective effects in animals models of ischemia (Liu et al., 2014a, PopaWagner et al., 2010 and Solaroglu et al., 2006), including the neonatal rat HI model
(Fathali et al., 2010 and Zhao et al., 2007). Previously, Fathali et al. (2010) reported that
G-CSF confers long-term neuroprotection by preventing brain atrophy and inducing
somatic growth, as well as improving sensorimotor and neurocognitive functions,
including limb placing, reflexes, short-term memory, muscle strength, exploratory
behavior, and motor coordination in a neonatal HI rodent model.
Many pathways are activated by stimulating the G-CSF (G-CSFR), such as the
Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, the
Ras/mitogen activated protein kinase (MAPK) pathway, and the phosphoinositide 3kinase (PI3K)/protein kinase B (Akt) pathway (Pap and Cooper, 1998 and Solaroglu et
al., 2007). Of interest to this study, the PI3K/Akt pathway has been implicated in
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stabilization of the blood-brain barrier (BBB) through decreased expression of VCAM-1
(Tsoyi et al., 2010), ICAM-1 (Radisavljevic et al. 2000), and b-catenin (Krafft et al.,
2013), and increased expressions of Claudins 3 and 5 (Krafft et al., 2013).
Glycogen synthase kinase (GSK-3β), which participates in a myriad of pathways
throughout the central nervous system, can be either neuroprotective or
neurodegenerative depending on the site of phosphorylation; GSK-3β activity is
increased by phosphorylation of tyrosine-216 and decreased by serine-9 phosphorylation
(Bhat et al., 2000, Grimes and Jope, 2001 and Valerio et al., 2011). While there is
substantial evidence that GSK-3β inhibition (tyrosine-216 dephosphorylation) reduces
neuronal apoptosis (Beurel and Jope, 2006, Krafft et al., 2012, Linseman et al., 2004 and
Song et al., 2010), experimental evidence of GSK-3β's effects on BBB stabilization and
attenuation of inflammation are limited.
A number of studies have linked GSK-3β with the PI3K/Akt pathway, showing
that phosphorylated Akt inactivates GSK-3β via tyrosine-216 dephosphorylation,
decreasing neuronal apoptosis (Krafft et al., 2012 and Krafft et al., 2013). In this study,
we investigate the role of G-CSF on the attenuation of inflammation and BBB disruption
in a neonatal HI model using P10 rats. Specifically, we hypothesize that G-CSF will
reduce pro-inflammatory markers, decrease adherens junction proteins, and increase tight
junction proteins via inactivation of GSK-3β through the G-CSFR/PI3K/Akt pathway.

Materials and Methods
Neonatal Hypoxia-Ischemia Injury Model
All of the experiments conducted in this study were approved by the Institutional
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Animal Care and Use Committee of Loma Linda University. A total of 150 post-natal
day 10 (P10) Sprague–Dawley rat pups (male and female), weighing 14–20 g, were used
in this study. To prepare for the neonatal hypoxia-ischemia model, all animals were
anesthetized with 3% isoflurane delivered with medical gas. After induction, confirmed
by the loss of a paw pinch reflex and monitored throughout the procedure, surgery began.
Unilateral HI surgery techniques were employed as previously described with P10
rat pups (Burchell et al., 2013 and Fathali et al., 2010). P10 pups were underwent a
unilateral right common carotid ligation. After surgery, animals recovered for 1 h and
were then placed into a hypoxia chamber with 8% O2 and 92% N2, which was
submerged in a water bath maintained at 37 °C for 2.5 h. The flow rate of the gas was
93.82 mL/min for the first 1.25 h and 77.30 mL/min for the final 1.25 h. After hypoxia,
all animals were returned to their dam.
The animal groups consisted of the following: (1) Sham, (2) HI, (3) HI + GSK-3β
siRNA, (4) HI + Control siRNA, (5) HI + G-CSF, (6) HI + G-CSF + Control siRNA, (7)
HI + G-CSF + G-CSFR siRNA, (8) HI + G-CSF + DMSO (Dimethyl sulfoxide) (vehicle
for Wortmannin), and (9) HI + G-CSF + Wort (Wortmannin). Sham animals underwent
the HI surgical procedures (i.e. exposure of the common carotid artery) without artery
ligation and without exposure to hypoxic conditions.

Experimental Conditions and Pharmacological Interventions
The role of the G-CSFR/PI3K/Akt/GSK-3β signaling pathway for preventing
BBB disruption and neuroinflammation after HI was examined using the following
antagonists: G-CSFR siRNA, Control siRNA, Wortmannin, and GSK-3β siRNA.
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After exposure to the hypoxia chamber, 134 injured animals were treated with GCSF 50 μg/kg (Amgen Inc., Thousand Oaks, CA, USA) in PBS administered
subcutaneously 1 h after completion of the HI procedure (1 h after pups are removed
from the hypoxia chamber) (Doycheva et al., 2013). To understand the effects of various
antagonists with G-CSF treatment, the following groups were studied: HI + G-CSF (no
antagonist), HI + G-CSF + Control siRNA, HI + G-CSF + G-CSFR siRNA, HI + G-CSF
+ DMSO, and HI + G-CSF + Wortmannin.
For the HI + GSK-3β siRNA group, two different GSK-3β siRNAs (21500 R121717, R12-1719, Cell Signaling Technology, Inc. Danvers, MA, USA), with a total
volume of 4 μL (2 μL of each) were stereotaxically injected with a 10 μL syringe
(Hamilton, Nevada, USA), 1.5 mm posterior and 1.5 mm lateral to the bregma and 1.7
mm deep from the skull in the ventricle of the contralateral hemisphere 48 h prior to HI.
The HI surgery followed the procedure outlined above. The HI + Control siRNA group
followed the same method except Control siRNA (4 μL, Santa Cruz Biotechnology, Inc.,
CA, USA) was also given.
For the HI + G-CSF + G-CSFR group, 2 μL of 0.4 nM G-CSFR siRNA (G-CSFR
siRNA, Santa Cruz Biotechnology Inc. CA, USA, resuspended in RNA-free water) was
administered 1.5 mm posterior and 1.5 mm lateral to the bregma, and 1.7 mm deep from
the skull in the contralateral hemisphere 48 h prior to HI. HI surgery and G-CSF
treatment were described above. The HI + G-CSF + Control siRNA group followed the
same procedure except Control siRNA (2 μL, Santa Cruz Biotechnology, Inc., CA, USA)
was used instead of the G-CSFR siRNA.
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Wortmannin (86 ng/pup diluted in 2% DMSO, Cell Signaling Technology, Inc.
Danvers, MA, USA) was administered 2.0 mm posterior and 2.0 mm lateral to the
bregma, and 2.0 mm deep to the skull surface at the contralateral hemisphere 1 h prior to
HI surgery. The same volume of 2% DMSO (diluted in saline, Sigma Aldrich, St. Louis,
MO, USA) was administered as control.

Time Course of β-catenin Phosphorylation, β-catenin, IKKβ, and NF-κB Expression
after HI
A total of 30 animals were sacrificed at 0, 12, 24, 48, or 72 h (n = 6 per time
point) after HI surgery. Western blot was performed in order to investigate any changes
in p-β-catenin, β-catenin, IKKβ, and NF-κB following HI. The ipsilateral hemispheres
were then isolated and analyzed for protein expressions.

Expression of β-catenin Phosphorylation, β-catenin, IKKβ, and NF-κB 48 h following
HI after GSK-3β siRNA
Twelve animals were divided between the HI + Control siRNA and HI + GSK-3β
siRNA groups (n = 6 in each group) in order to measure the expression of p-β-catenin, βcatenin, IKKβ, and NF-κB after the administration of GSK-3β siRNA following HI. The
ipsilateral hemispheres were isolated and analyzed by Western blot. The Sham and HI
animals were shared with the 48 h time course expression groups.
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Evan's Blue Dye Extravasation
Four percent Evans blue (EB) solution in 0.1 M PBS was injected subcutaneously
(0.04 mL/15 g body weight) (Fernandez-Lopez et al., 2012) 26–28 h after HI and left to
circulate for 20–22 h. The pups were then anesthetized and transcardially perfused with
50 mL of 0.1 M PBS, the brains removed and cut into 2 mm slices with a rat brain matrix
48 h after HI, then separated into the contralateral and ipsilateral hemispheres. The
amount of EB in the ipsilateral hemisphere (weighed before homogenized) was measured
with a spectrophotometer (Genesys 10S UV-Vis, Thermo Fisher Scientific Inc. Waltham,
MA, USA) to evaluate blood–brain barrier (BBB) permeability. The Evans blue
extravasation was quantified as μg Evans blue/g tissue using a standard curve. Evans blue
data for all groups was normalized to the value of the Sham group.

Immunohistochemistry
Anesthetized pups were transcardially perfused with 0.1 M PBS followed by 4%
formaldehyde solution (PFA) 48 h after HI. The brains were then removed, postfixed (4%
PFA, 4 °C, 24 h), and then transferred into a 30% sucrose solution for 2 days. The
cryoprotected brains were sectioned at a thickness of 10 μm with a cryostat (LM3050S,
Leica Microsystems Inc, IL, USA) for double fluorescence staining. The sections were
then washed three times with 0.1 M PBS and were incubated with blocking solution
(10% normal goat serum in 0.1 M PBS) for 2 h at room temperature following
0.1%Triton X-100 (37 °C, 30 min). Primary antibodies anti-GFAP (1:200, Millipore,
Billerica, MA, USA), anti-vWF (1:200, Millipore, Billerica, MA, USA), anti-G-CSFR
(1:100, Santa Cruz Biotechnology, Inc., CA, USA), anti-p-GSK-3β (Tyr216,1:200,
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abcam, Cambridge, MA,USA), anti-β-catenin (1:200, abcam, Cambridge, MA, USA),
anti-MPO (1:100, Santa Cruz Biotechnology, Inc., CA, USA), and DAPI (Vector
Laboratories Inc. Burlingame, CA, USA) were applied (4 °C, overnight).
The sections were then washed with 0.1 M PBS and incubated for 2 h with
secondary antibodies (1:200, anti-mouse IgG labeled with Alexa Fluor-488, anti-rabbit
IgG labeled with Alexa Fluor-568, Jackson ImmunoResearch Laboratories, Inc. West
Grove, PA, USA) at room temperature. The stained slices were observed with an
OLYMPUS BX51 microscope.

Western Blot
Western blot was performed as described previously (Chen et al., 2008). Animals
were euthanized at the various time points after HI. After intracardiac perfusion with cold
PBS (pH 7.4) solution, the brains were removed and separation into ipsilateral and
contralateral cerebrums. Samples were frozen with liquid nitrogen and stored at − 80 °C
until analysis occurred. The whole-cell lysates were obtained by homogenizing with
RIPA lysis buffer (sc-24948, Santa Cruz Biotechnology, Inc., TX, USA) and were
centrifuged at 14,000 g at 4 °C for 30 min. The supernatant was used as a whole-cell
protein extract, and the protein concentration was measured by using a detergent
compatible assay (Bio-Rad, Dc protein assay). Equal amounts of protein (50 μg) were
loaded to a 10% SDS–PAGE gel. After being electrophoresed and transferred to a
nitrocellulose membrane, the membrane was blocked with 5% non-fat blocking grade
milk (Bio-Rad, Hercules, CA, USA) and incubated with the primary antibody overnight
at 4 °C. The primary antibodies used were anti-actin (47 kDa, 1:4000, Santa Cruz
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Biotechnology, Inc., CA, USA), anti-G-CSFR (90 kDa, 1:5000, Santa Cruz
Biotechnology, Inc., CA, USA), anti-p-GSK-3β (Tyr216) (49 kDa), anti-GSK-3β (47
kDa), anti-β-catenin (94 kDa), anti-p-β-catenin (94 kDa, 1:10000, abcam, Cambridge,
MA,USA), anti-MPO (150 kDa), anti-Claudin-3 (23 kDa), anti-p120-catenin (94 kDa),
anti-Claudin-5 (23 kDa), anti-IL-1β (17.5 kDa), anti-IL-10 (18 kDa), anti-IL-12 (75 kDa),
anti-IKΚβ (87 kDa), anti-NF-κB (64 kDa) (1:4000, Santa Cruz Biotechnology, Inc., CA,
USA), and anti-polyclonal antitumor necrosis factor-α (anti-TNF-α) (52 kDa, 1:10000,
Millipore, Billerica, MA,USA).
The nitrocellulose membranes were incubated with secondary antibodies (Santa
Cruz Biotechnology, Inc., CA, USA) for 2 h at room temperature. Immunoblots were
then probed via ECL Plus chemiluminescence reagent kit (Fisher Scientific International,
Inc. Pittsburgh, PA, USA) and analyzed using Image J (4.0, Media Cybernetics, Silver
Springs, MD). Western blot data were presented as the ratio of the target protein's pixel
intensities to the pixel intensities of β-actin. For β-catenin, the pixels of p-β-catenin were
divided by the pixels of β-catenin (to obtain the ratio of β-catenin, which was
phosphorylated to that of the total available β-catenin). The p-β-catenin/β-catenin ratio
was then normalized to the pixels of β-actin. All target protein ratios were then
normalized to the Sham group's ratio of the pixel intensities.

Statistics
All the data were expressed as mean ± SEM. Statistical differences between
groups for each outcome measured were analyzed using one-way ANOVA followed by
Tukey post hoc. A p < 0.05 was considered to be statistically significant.

119

Result
Time Course Expression of p-β-catenin/β-catenin, IKKβ and NF-κB after HI
The ratio of p-β-catenin/β-catenin and the expression of IKKβ and NF-κB in
response to HI were examined at four times post-ictus (Fig. 1). Representative western
blots are shown for each protein (Fig. 1D). The ratio of p-β-catenin to β-catenin to β-actin
(p-β-catenin/ β-catenin/β-actin) expression was low in Sham but, after HI, it gradually
increased over 12 h (p < 0.05 vs. Sham) to 24 h (p < 0.05 vs. Sham), peaking
significantly at 48 h (p < 0.05 vs. Sham).
By 72 h, the p-β-catenin/β-catenin/β-actin ratio had significantly decreased
compared to the 48 h time point (p < 0.05 vs. Sham, 12 h, 24h, and 48 h) (Fig. 1A).
IKKβ and NF-κB showed similar expression patterns, in which both proteins' levels had
low expression in the Sham group which significantly increased at 12 h (p < 0.05 vs.
Sham for IKKβ/β-actin, p < 0.05 vs. Sham for NF-κB/β-actin) reaching a maximum at 48
h (p < 0.05 vs. Sham for IKKβ/β-actin, p < 0.05 vs. Sham for NF-κB/β-actin). Both
IKKβ/β-actin and NF-κB/β-actin began decreasing by 72 h (p < 0.05 vs. Sham, 12 h, 24
h, and 48 h groups for IKKβ/β-actin, p < 0.05 vs. Sham, 12 h, 24 h, and 48 h groups for
NF-κB/β-actin) (Fig. 1B, C).
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Fig. 14. Expression ratios of p-β-catenin/β-actin, β-catenin/β-actin, IKKβ/β-actin, and NFκB/β-actin 12, 24, 48, and 72 h following HI. (A) Transient response of the p-β-catenin/βcatenin/β-actin ratio following HI (n = 6/group). (B) Transient response of IKKβ/β-actin
ratio following HI (n = 6/group). (C) Transient response of NF-κB/β-actin ratio following
HI (n = 6/group). (D) Representative Western blot of p-β-catenin, β-catenin, IKKβ, NFκB, and β-actin for Sham and HI (12, 24, 48, and 72 h post-HI) animals. All graphs: *p <
0.05 vs. Sham group, #p < 0.05 vs.12 h post-HI group, †p < 0.05 vs. 24 h post-HI group,
‡p < 0.05 vs. 48 h post-HI group.
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Expression of p-β-catenin/β-catenin, IKKβ, and NF-κB after GSK-3β siRNA Pretreatment 48 h Post-HI
The effects of GSK-3β siRNA on the expression levels of the p-β-catenin/βcatenin ratio, IKKβ, and NF-κB were measured (Fig. 2). The levels of p-β-catenin/βcatenin/β-actin, IKKβ/β-actin, and NF-κB/β-actin expression in the HI groups were
significantly higher when compared to the Sham levels (p < 0.05 vs. Sham for p-βcatenin/β-catenin/β-actin, IKKβ/β-actin, and NF-κB/β-actin). After HI, GSK-3β
knockdown by siRNA significantly reduced the expression of these proteins compared to
HI (p < 0.05 vs. HI for p-β-catenin/β-catenin/β-actin, IKKβ/β-actin, and NF-κB/β-actin),
while control siRNA did not alter any of these proteins' expressions compared to HI (p >
0.05 vs. HI for p-β-catenin/β-catenin/β-actin, IKKβ/β-actin, and NF-κB/β-actin).
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Fig. 15. Effect of GSK-3β siRNA on the p-β-catenin/β-catenin/β-actin and IKKβ/β-actin
and NF-κB/β-actin expression ratios 48 h after HI. (A) Effect of GSK-3β siRNA on the pβ-catenin/β-catenin/β-actin ratio (n = 6/group). (B) Effect of GSK-3β siRNA on IKKβ/βactin ratio (n = 6/group). (C) Effect of GSK-3β siRNA on the NF-κB/β-actin ratio
(n = 6/group). (D) Representative western blot of p-β-catenin, β-catenin, IKKβ, NF-κB,
and β-actin for Sham, HI, HI + GSK-3β siRNA, and HI + Control siRNA animals. All
graphs: *p < 0.05 vs. Sham group, #p < 0.05 vs. HI only group, †p < 0.05 vs. HI + GSK3β siRNA group.
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G-CSF Reduced Evans Blue Extravasation 48 h after HI
The amount of ipsilateral hemisphere Evans blue extravasation was significantly
higher in the HI group compared to Sham (p < 0.05) (Fig. 3). Both G-CSF treatment and
GSK-3β knockdown by siRNA significantly reduced the extravasation of Evans blue
compared to HI only (p < 0.05 vs. HI for HI + G-CSF, p < 0.05 vs. HI for HI + GSK-3β
siRNA). The neuroprotective effects of G-CSF after HI were unaffected by DMSO or
control siRNA (p < 0.05 vs. HI for DMSO, p < 0.05 vs. HI for control siRNA, p > 0.05
vs. HI + G-CSF for DMSO, p > 0.05 vs. HI + G-CSF for control siRNA). The inhibition
of Akt by Wortmannin and G-CSFR knockdown by siRNA completely prevented the
neuroprotective effects of G-CSF after HI (p < 0.05 vs. Sham, HI + G-CSF, and HI +
GSK-3β siRNA for Wortmannin, p < 0.05 vs. Sham, HI + G-CSF, and HI + GSK-3β
siRNA for G-CSFR siRNA).
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Fig. 16. Evans blue extravasation 48 h after HI. Brain slices with extravasated dye
demonstrate the effect of G-CSF (administered 1 h after removal from the hypoxia
chamber) and G-CSF/GSK-3β pathway inhibitors on BBB permeability. The extravasated
dye from the brain slices is quantitatively evaluated (μg of Evan's Blue dye per g of brain
tissue, normalized to Sham) (n = 6/group). Graph: *p < 0.05 vs. Sham group, #p < 0.05 vs.
HI only group, †p < 0.05 vs. HI + G-CSF group, ‡p < 0.05 vs. HI + GSK-3β siRNA group,
&p < 0.05 vs. HI + G-CSF + DMSO group, @p < 0.05 vs. HI + G-CSF + Wortmannin, Ŧp
< 0.05 vs. HI + G-CSFR siRNA group.

125

Immunohistochemistry Showed Co-localization of G-CSFR with Endothelial cells 48 h
after HI
Immunohistochemical analysis showed that G-CSFR localizes on endothelial cells
(vWF) but not astrocytes (GFAP) and p-GSK-3β also localizes within endothelial cells.
These results show that both the G-CSFR and p-GSK3β are localized in endothelial cells
(Fig. 4).
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Fig. 17. Expression and localization of G-CSFR 48 h following HI. Top row: representative
immunohistochemistry images showing G-CSFR does not localize on astrocytes (GFAP:
red, G-CSFR: green, DAPI: blue). Middle row: representative immunohistochemistry
images showing localization of G-CSFR on blood vessels (vWF: red, G-CSFR: green,
DAPI: blue). Bottom row: representative immunohistochemistry images showing
localization of p-GSK-3β on blood vessels (vWF: red, p-GSK-3β: green, DAPI: blue) (n =
3/group). Scale bars: 25 μm.
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Expression of p-β-catenin/β-catenin and p120-catenin 48 h after HI
The ratio of p-β-catenin/β-catenin/β-actin was significantly increased in the HI
group compared to Sham (p < 0.05 vs. Sham), which was decreased by G-CSF treatment
(p < 0.05 vs. HI). Wortmannin and G-CSFR siRNA both prevented the decreased
expression by G-CSF treatment and also showed no changes in the ratio of p-β-catenin/βcatenin/β-actin when compared to HI (p > 0.05 vs. HI for Wortmannin, p > 0.05 vs. HI
for G-CSFR siRNA, p < 0.05 vs. HI + G-CSF for Wortmannin, p < 0.05 vs. HI + G-CSF
for G-CSFR siRNA) (Fig. 5A, C).
p120-catenin/β-actin levels decreased after HI (p < 0.05 vs. Sham) but were restored to
Sham levels with G-CSF treatment (p > 0.05 vs. Sham, p < 0.05 vs. HI). Wortmannin and
G-CSFR siRNA lowered p120-catenin/β-actin levels to those of the HI group (p < 0.05
vs. Sham and HI + G-CSF for Wortmannin, p < 0.05 vs. Sham and HI + G-CSF for GCSFR siRNA, p > 0.05 vs. HI for Wortmannin, p > 0.05 vs. HI for G-CSFR siRNA) (Fig.
5B, C).
Representative immunohistochemical images showed decreased expression of βcatenin in the HI, HI + G-CSF + Wort, and HI + G-CSF + G-CSFR siRNA groups
compared to Sham, while G-CSF treatment and GSK-3β knockdown by siRNA had
similar expressions as Sham (Fig. 5E).
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Fig. 18. Effect of G-CSFR siRNA on the p120-catenin/β-actin and p-β-catenin/β-catenin/βactin expression ratios 48 h following HI. (A) Effect of G-CSFR siRNA on the p-βcatenin/β-catenin/β-actin ratio (n = 6/group). (B) Effect of G-CSFR siRNA on the
expression ratio of p120-catenin/β-actin (n = 6/group). (C) Representative western blot of
p-β-catenin, β-catenin, p120-catenin, and β-actin for Sham, HI only, HI + G-CSF, HI + GCSF + Wortmannin, and HI + G-CSF + G-CSFR siRNA animals. (D) Representative brain
slice (stained with TTC, red color indicates non-ischemic tissue, white color indicates
ischemic tissue) and area (box) used for immunohistochemistry imaging. (E)
Representative immunohistochemistry images for β-catenin expression following HI.
Scale bars: 25 μm. Graph: *p < 0.05 vs. Sham group, #p < 0.05 vs. HI only group, †p <
0.05 vs. HI + G-CSF group.
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Claudin-3 and Claudin-5 Expressions 48 h after HI
Both Claudin-3/β-actin and Claudin-5/β-actin expression levels were decreased
by HI compared to Sham (p < 0.05 vs. Sham for Claudin-3/β-actin, p < 0.05 vs. Sham for
Claudin-5/β-actin), while G-CSF treatment restored both claudins' levels back to normal
(p > 0.05 vs. Sham and p < 0.05 vs. HI for Claudin-3/β-actin, p > 0.05 vs. Sham and p <
0.05 vs. HI for Claudin-5/β-actin). Wortmannin and G-CSF siRNA similar expression
levels of Claudin-3/β-actin as HI group, preventing the effect of G-CSF (p < 0.05 vs.
Sham and HI + G-CSF for Wortmannin, p < 0.05 vs. Sham and HI + G-CSF for G-CSFR
siRNA, p > 0.05 vs. HI for Wortmannin, p > 0.05 vs. HI for G-CSFR siRNA). Claudin5/β-actin expression was lower for both Wortmannin and G-CSFR knockdown by siRNA
than the Sham, HI, and HI + G-CSF groups (p < 0.05 vs. Sham, HI, and HI + G-CSF for
Wortmannin, p < 0.05 vs. Sham, HI, and HI + G-CSF for G-CSFR siRNA) (Fig. 6).

Expression of MPO, VCAM-1, and ICAM-1 48 h after HI
The level of MPO/β-actin was significantly increased in the HI group compared to
Sham (p < 0.05 vs. Sham). G-CSF treatment restored the MPO/β-actin level back to
Sham levels (p > 0.05 vs. Sham, p < 0.05 vs. HI). The inhibition of Akt by Wortmannin
and G-CSFR knockdown by siRNA both reversed G-CSF's neuroprotective effect by
increasing MPO/β-actin levels back to that of HI (p < 0.05 vs. Sham and HI + G-CSF for
Wortmannin, p < 0.05 vs. Sham and HI + G-CSF for G-CSFR siRNA, p > 0.05 vs. HI for
Wortmannin, p > 0.05 vs. HI for G-CSFR siRNA) (Fig. 7A).
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Fig. 19. Effect of G-CSFR siRNA on the ratios of Claudin-3/β-actin and Claudin-5/β-actin
48 h following HI. (A) Effect of G-CSFR siRNA on the ratio of Claudin-3/β-actin (n =
6/group). (B) Effect of G-CSFR siRNA on the ratio of Claudin-5/β-actin (n = 6/group).
Both Graphs: *p < 0.05 vs. Sham group, #p < 0.05 vs. HI only group, †p < 0.05 vs. HI +
G-CSF group.
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Fig. 20. Effect of G-CSFR siRNA on the ratios of VCAM-1/β-actin and ICAM-1/β-actin
48 h following HI. (A) Effect of G-CSFR siRNA on the ratio of MPO/β-actin (n = 6/group).
(B) Effect of G-CSFR siRNA on the ratio of VCAM-1/β-actin (n = 6/group). (C) Effect of
G-CSFR siRNA on the ratio of ICAM-1/β-actin (n = 6/group). (D) Representative
immunohistochemistry images for MPO/β-actin ratio following HI. Scale bars: 25 μm. The
area used for immunohistochemistry imaging is the same as that in Fig. 5D. All graphs: *p
< 0.05 vs. Sham group, #p < 0.05 vs. HI only group, †p < 0.05 vs. HI + G-CSF group.
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HI significantly increased both VCAM-1/β-actin and ICAM-1/β-actin adhesion molecule
levels compared to Sham (p < 0.05 vs. Sham for VCAM-1/β-actin, p < 0.05 vs. Sham for
ICAM-1/β-actin). Both adhesion molecules' expressions were decreased by G-CSF (p <
0.05 vs. HI for VCAM-1/β-actin, p < 0.05 vs. HI for ICAM-1/β-actin). Once again
Wortmannin-induced Akt inhibition and G-CSFR knockdown reversed G-CSF's
neuroprotective effect and the levels of VCAM-1/β-actin, and ICAM-1/β-actin remained
unchanged compared to HI group (p < 0.05 vs. Sham and HI + G-CSF for VCAM-1/βactin, p < 0.05 vs. Sham and HI + G-CSF for ICAM-1/β-actin, p > 0.05 vs. HI for
VCAM-1/β-actin, p > 0.05 vs. HI for ICAM-1/β-actin) (Fig. 7B, C).
Immunohistochemical analysis was performed (brain area shown in Fig. 5D) on
the above mentioned groups for MPO showed the same trend as that from the western
blots. Furthermore, GSK-3β siRNA showed a decreased expression of MPO compared to
HI group (Fig. 7D).

Expression of IKKβ, NF-κβ, TNF-α, IL-1β, IL-10, and IL-12 48 h after HI
The expression levels of IKKβ/β-actin, NF-κB/β-actin, TNF-α/β-actin, IL-1β/βactin, and IL-12/β-actin were significantly increased after HI compared to Sham (p < 0.05
vs. Sham for all expressions) while G-CSF treatment reduced the effect (p < 0.05 vs. HI
for all expressions, p < 0.05 vs. Sham for all expressions). Neither Wortmannin nor GCSFR knockdown changed the expression levels of the these targets compared to HI (p >
0.05 vs. HI for all expressions for Wortmannin, p > 0.05 vs. HI for all expression for GCSFR siRNA, p < 0.05 vs. Sham and G-CSF for all expressions for Wortmannin, p <
0.05 vs. Sham and G-CSF for all expressions for G-CSFR siRNA) (Fig. 8A–D, F).
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Fig. 21. Effect of G-CSFR siRNA on the ratios of IKKβ/β-actin, NF-κB/β-actin, TNF-α/βactin, IL-1β/β-actin, IL-10/β-actin, and IL-12/β-actin 48 h following HI. (A) Effect of GCSFR siRNA on the ratio of IKKβ/β-actin (n = 6/group). (B) Effect of G-CSFR siRNA on
the ratio of NF-κB/β-actin (n = 6/group). (C) Effect of G-CSFR siRNA on the ratio of TNFα/β-actin (n = 6/group). (D) Effect of G-CSFR siRNA on the ratio of IL-1β/β-actin (n =
6/group). (E) Effect of G-CSFR siRNA on the ratio of IL-10/β-actin (n = 6/group). (F)
Effect of G-CSFR siRNA on the ratio of IL-12/β-actin (n = 6/group). All graphs: *p < 0.05
vs. Sham group, #p < 0.05 vs. HI only group, †p < 0.05 vs. HI + G-CSF group.
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Simultaneously, IL-10/β-actin was significantly decreased in the HI group (p < 0.05 vs.
Sham) and increased to Sham levels after G-CSF treatment (p > 0.05 vs. Sham, p < 0.05
vs. HI). Once again, Wortmannin and G-CSFR knockdown had similar expression levels
of IL-10/β-actin as the HI group (p < 0.05 vs. Sham for Wortmannin, p > 0.05 vs. HI for
Wortmannin, p < 0.05 vs. Sham for G-CSFR siRNA, p > 0.05 vs. HI for G-CSFR
siRNA) (Fig. 8E).

Discussion
In this study, G-CSF was found to stabilize the BBB and reduce a number of
inflammatory markers. Various interventions of the proposed G-CSF/Akt/GSK-3β
pathway were utilized, all of which prevented G-CSF's protective and anti-inflammatory
effects.
G-CSF, a widely studied growth factor for stroke treatment, is neuroprotective in
rodent models of cerebral ischemia (Schabitz et al., 2003, Shyu et al., 2004 and Yanqing
et al., 2006) and neonatal hypoxia-ischemia (Doycheva et al., 2013). The anti-apoptotic
effects of G-CSF are reported to reduce infarct volume and improve neurological
outcomes after experimental cerebral ischemia (Gibson et al., 2005 and Schabitz et al.,
2003) and neonatal hypoxia-ischemia (Doycheva et al., 2013). While G-CSF
administration has been proven to reduce infarct volume, studies reporting the effects of
G-CSF on brain edema and BBB after injury are limited and conflicting. In a rat model of
traumatic brain injury, G-CSF was ineffective at reducing brain edema (Sakowitz et al.,
2006). However, Gibson et al. (2005) found that G-CSF reduces cerebral edema after
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middle cerebral artery occlusion in mice. Furthermore, the results by Gibson et al. (2005)
suggest that G-CSF suppresses IL-1β mRNA expression.
Our current study examined a potential mechanism by which G-CSF treatment
attenuates BBB disruption and neuroinflammation in a neonatal rat model of hypoxiaischemia. More specifically, G-CSF elicited BBB stabilization by G-CSFR stimulation
and activation of the PI3K/Akt pathway and resultant downstream inactivation of GSK3β (Pap and Cooper, 1998 and Solaroglu et al., 2007). Our lab has recently demonstrated
that phosphorylation of tyrosine-216 in GSK-3β plays a crucial role in regulating
neuronal apoptosis through caspase-3 in a mouse model of intracerebral hemorrhage
(Krafft et al., 2012). Additionally, activated Akt (p-Akt) has the ability to phosphorylate
serine-9, which inactivates GSK-3β and reduces the amount of GSK-3β available for
activation (through the tyrosine-216 form), ultimately decreasing apoptosis (Hummler et
al., 2013 and Krafft et al., 2012). The inactivation of GSK-3β, specifically through
serine-9 phosphorylation and tyrosine-216 dephosphorylation, increased β-catenin, an
important factor in maintaining the BBB (Lin et al., 2009). Furthermore, GSK-3β
inactivation may also decrease NF-κB expression, thereby reducing neuroinflammation
(Krafft et al., 2013).
Findings in the present study indicate that G-CSF is capable of reducing BBB
disruption through decreased β-catenin phosphorylation and p120-catenin
phosphorylation via G-CSFR/PI3K/Akt/GSK-3β pathway. G-CSFR siRNA was
associated with increased β-catenin activation and decreased activation of p120-catenin,
while GSK-3β siRNA had the reverse effects. Evidence supporting enhanced BBB
stabilization by G-CSF-induced G-CSFR/PI3K/Akt/GSK-3β pathway activation in
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endothelial cells includes decreased adheren (VCAM-1 and ICAM-1) and increased tight
junction (Claudin3 and 5) proteins. Together, our findings indicate that the activation of
the G-CSFR/Akt/GSK-3β pathway by G-CSF plays a critical role in BBB stabilization.
We additionally examined the role G-CSF plays in modulating
neuroinflammation by measuring expression levels of several cytokines; administering
G-CSF attenuated pro-inflammatory cytokines (IKKβ, NF-κB, TNF-α, IL-1β, and IL-12)
and enhanced an anti-inflammatory cytokine (IL-10). Our results agree with those by
Gibson et al. (2005), indicating that G-CSF suppresses pro-inflammatory cytokines. The
assessment of neutrophil infiltration via MPO staining shows decreased MPO expression
following G-CSF treatment. The G-CSF-induced suppression of pro-inflammatory
markers and the upregulation of anti-inflammatory markers are reversed by G-CSFR
siRNA, further implicating the G-CSFR/Akt/GSK-3β pathway in preventing
neuroinflammation after HI.

Are Additional Studies on G-CSF Required?
Recent experimental studies, including this one, indicate that G-CSF treatment
remains a promising therapy due to its anti-apoptotic, anti-inflammatory, and BBB
stabilizing effects. Although G-CSF has been largely successful in experimental models
of ischemic brain injury, G-CSF failed to improve clinical outcome of adult ischemic
stroke patients in the recent AX2000 clinical trial (Ringelstein et al., 2013). Possible
explanations for its clinical failure include a reduced therapeutic effect from G-CSF due
to rt-PA, an excessively long therapeutic window, and a limited number of centers
involved in the trial (Ringelstein et al., 2013). First, the administration of rt-PA may
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reduce G-CSF's beneficial effects by weakening the endothelium. Second, the length of
time until treatment with G-CSF was 6.8 h post-ictus. By this time, a significant amount
of irreversible damaged will have already occurred (An et al., 2014 and Lapchak, 2013),
thus G-CSF's therapeutic benefit will be severely limited.
Additionally, a significant number of pathophysiological differences exist
between adults and newborns, including differences in their responses to hypoxic
ischemic injury and its treatments (Blomgren and Hagberg, 2013, Vexler et al., 2006a
and Vexler et al., 2006b). Finally, G-CSF provides increased neuroprotection from
ischemic brain injury in neonates (Charles et al., 2012) compared to adults (Solaroglu et
al., 2009); G-CSF treatment (50 μg/kg) caused a 50% reduction in infarction volume
following neonatal HI (Charles et al., 2012) compared to a 22% reduction following adult
cerebral ischemia (Solaroglu et al., 2009).
There are three ongoing clinical trials evaluating G-CSF treatment for stroke:
“Study to determine the effect of a drug called Neupogen on stroke recovery (GIST),”
“Establishment of clinical basis for hematopoietic growth factors therapy in brain injury,”
and “The variation of movement related cortical potential, cortio-cortical inhibition, and
motor evoked potential in intracerebral implantation of antologous peripheral blood stem
cells (CD34) in old ischemic stroke” (Liu et al., 2014b). However, all three of these trials
examine G-CSF treatment in adult patients, and none have yet released results on GCSF's therapeutic benefit.
In the current study, G-CSF plays a critical role in preventing BBB disruption and
neuroinflammation via G-CSFR/PI3K/Akt pathway activation and downstream
inactivation of GSK-3β. G-CSFR, previously reported to be expressed on neurons, is also
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expressed on other cells of the neurovascular unit, supporting it as a promising
therapeutic target (Leak et al., 2014). Combined with the limitations from the AX2000
clinical trial, this study warrants continued research on G-CSF treatment, possibly by
using large animal models (Ramanantsoa et al., 2013 and Tajiri et al., 2013) following the
guidelines for effective translational research (Chen et al., 2014 and Lapchak et al., 2013)
as well as examining G-CSF's neuroprotective effects after ischemic brain injury in
another clinical trial. Finally, future clinical trials should examine G-CSF's effects after
hypoxic ischemia in newborns.

Conclusion
Here we report attenuation of neuroinflammation and BBB disruption by G-CSFinduced G-CSFR/PI3K/Akt pathway activation and subsequent GSK-3β inactivation. GCSFR was localized to endothelial cells but not astrocytes. Future studies should include
determining whether G-CSF stabilizes the BBB, thereby reducing peripheral immune cell
infiltration, or G-CSF reduces immune cell infiltration, thus maintaining BBB integrity.
Additional studies should also include examining the role of G-CSF in reducing cerebral
edema and the mechanism(s) by which G-CSF-mediated GSK-3β inactivation decreases
VCAM and ICAM and increases the expression of claudins.
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Abstract
Osteopontin (OPN) is a neuroprotective molecule that is upregulated following
rodent neonatal hypoxic-ischemic (nHI) brain injury. Because Rac1 is a regulator of
blood-brain barrier (BBB) stability, we hypothesized a role for this in OPN signaling.
nHI was induced by unilateral ligation of the right carotid artery followed by hypoxia (8
% oxygen for 2 h) in P10 Sprague-Dawley rat pups. Intranasal (iN) OPN was
administered at 1 h post-nHI. Groups consisted of: (1) Sham, (2) Vehicle, (3) OPN, and
(4) OPN + Rac1 inhibitor (NSC23766). Evans blue dye extravasation (BBB permeability)
was quantified 24 h post-nHI, and brain edema at 48 h. Increased BBB permeability and
brain edema following nHI was ameliorated in the OPN treatment group. However, those
rat pups receiving OPN co-treatment with the Rac1 inhibitor experienced no
improvement compared with vehicle. OPN protects the BBB following nHI, and this was
reversed by Rac1 inhibitor (NSC23766).
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Introduction
Neonatal hypoxic-ischemic brain injury remains a leading cause of mortality and
morbidy, affecting 2-4 of 1,000 full-term and nearly 60% of premature infants [1,2].
Among survivors, 20-40% develop significant neurological impairments, associated with
life-long medical, social, and emotional difficulties [3]. Recent studies have demonstrated
neuroprotective effects of intracerebroventricular (ICV) administration of recombinant
osteopontin (rOPN) [4]. Previouslt, rOPN was shown to have reduced cell death,
stabilized the blood-brain barrier (BBB), and improved neurological impairments in
rodents subjected to brain injury [5].
In sum, osteopntin (OPN) is a neuroprotective molecule that is upregulated following
rodent neonatal hypoxic-ischemic brain injury [5,6]. OPN, an extracellular matrix
protein, stimulates cell surface integrin receptors, which induce the phosphorylation of
focal adhesion kinase (FAK) [4,7,8] which induces Rac-1, a downstream target of FAK
that has been shown to stabilize the BBB after HI insult [9]. Because Rac1 is a regulator
of BBB stability [10-13], we hypothesized a role for this in OPN signaling.

Methods
Neonatal hypoxia-ischemia was induced by unilateral ligation of the right carotid
artery followed by hypoxia (8% oxygen for 2.5h) in P10 Sprague-Dawley rat pups.
Intranasal (iN) OPN was administered at 1 h post-nHI. Groups consisted of: (1) Sham, (2)
Vehicle, (3) OPN, and (4) OPN+Rac1 inhibitor (NSC23766). Evans blue dye
extravasation (BBB permeability) was quantified 24 h post-nHI, brain edema at 48 h.
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Animal Surgery
After induction of anesthesia, the neck of the rats was prepared and draped using
standard sterile techniques. Skin preparation consisted of alcohol swabbing of the neck.
Next, a small midline neck incision on the anterior neck was made with a No. 11 blade
surgical knife. This incision was approximately 3-5 mm in length. Using gentle blunt
dissection, the right carotid artery was isolated and gently separated from surrounding
structures, including the vagus nerve, trachea, and esophagus. The carotid artery was then
ligated with 5-0 surgical suture. All bleeding was controlled with gentle pressure and
electrocautery as needed. After the carotid artery was ligated, the surgical field was
irrigated with several drops of saline, dried, and the skin closed with sutures. The entire
surgical procedure took approximately 10 minutes. After the surgical procedure was
completed, the rats were allowed to wake and recover for 1 h. This recovery occurred in a
temperature-controlled incubator. Throughout the surgical and post-operative period,
temperature was controlled with heating blankets and incubators. After the rats
recovered, they were returned to the care of their mother. After the 1-h recovery period,
rats were exposed to hypoxia using the standard published protocols of the RiceVannucci model, done previously [14]. Exposure to hypoxia involved placing the animals
in a temperature-controlled chamber and then exposing them to 8% oxygen in balanced
nitrogen gas for 2.5 h. This hypoxic treatment was rendered in a specially designed
treatment chamber to prevent escape of the hypoxic gas mixture. Gas composition in the
chamber was monitored continuously with a monitor that measures oxygen and carbon
dioxide content. After hypoxic treatment all animals were monitored closely for any signs
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of distress, failure to thrive, infection, or serious disability. Immediately after hypoxia,
animals were returned to the care of their mother.

ICV Injection
Animals were anesthetized with isoflurane. A scalp incision was made on the
skull on the surface and the bregma exposed. Infusion of Rac1 inhibitor (NSC23766) was
performed using a 10-µl syringe (Hamilton Co., Reno, NV, USA) at the location 1.5 mm
posterior and 1.5 mm lateral to the bregma, and 1.7 mm deep to the skull surface at the
contralateral hemisphere 24 h before HI. Control rats were injected with 2% DMSO
(2µl/pup, diluted in saline; Sigma). The injection was completed in 5 min and the needle
maintained in the injection position for an additional 2 min. Then the needle was
removed slowly out of the brain and the wound sutured. After recovery from anesthesia,
the pups were returned to their dams.

Evans Blue
The spectrophotometric measurement of Evans blue dye [15, 16] was initiated
through intraperitoneal (IP) injection after nHI to measure BBB permeability. Under
anesthesia, Evans blue (Sigma-Aldrich) in normal saline (2%, 4 ml/kg) was infused. For
quantitative measurements, the brain hemisphers (hemorrhage) were homogenized in 3
ml of N, N-dimethylforamide (Sigma-Aldrich), incubated for 18 h at 55ºC, and then
centrifuged. Supernatants were analyzed at 620 nm by spectrophotometry, as routinely
performed [17].
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Brain Edema
Brain water content [15, 18-21] was measured using the wet-weight/dry-weight
method [17]. Following sacrifice, the brains were removed and divided. Tissue weights
were measured before and after drying for 24 h in a 100ºC oven. Weights were measured
using an analytical microbalance (model AE 100; Mettler Instrument Co., Colombus,
OH, USA) capable of precision within 1.0 µg. Brain edema was tabulated as percentage:
(wet weight – dry weight)/wet weight x 100.

Statistical Analysis
Significance was based on p<0.05. Data were statistically analyzed using one-way
analysis of variance (ANOVA), followed by Tukey post hoc test for significant analyses.
Statistical analyses were performed using SigmaPlot version 10.0 for Windows.

Results
A schematic of the proposed mechanism used as the basis of this preliminary
work is outlined (Fig. 1). Experimental data show significantly increased BBB
permeability (Fig. 2) and brain edema (Fig. 3) following nHI. These brain injuries were
significantly improved in the OPN treatment group. However, the rat pups receiving OPN
cotreatement with the Rac1 inhibitor experienced no improvement compared with vehicle
(please see Fig. 2), mechanistically reversing neuroprotection.
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Figure 22: Schematic, showing proposed mechanisms involving this preliminary investigation,
directives of further study.

Figure 23: OPN reduced brain edema. To determine the effects of OPN on BBB
permeability, brain water content, which is a measure of brain edema, was evaluated. Brain
edema was significantly increased in the ipsilateral hemisphere following HI induction.
OPN significantly reduced brain edema compared with vehicle group. The contralateral
hemisphere showed no increase in edema (*p<0.05 vs. sham; #p<0.05 vs. vehicle;
N=4/group).
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Figure 24: OPN reduced BBB permeability. To determine the effect of OPN on BBB
permeability, Evans blue dye extravasation as a measure of BBB permeability was
evaluated. OPN (5g) was administered following HI induction, and HI significantly
increased Evans blue dye extravasation, as seen in the ipsilateral hemisphere, which was
significantly attenuated by OPN treatment.
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Conclusion
Translational stroke studies, including animal modeling, are greatly needed to
safely integrate basic preclinical scientific principles ahead of clinical application [2226]. Numerous attempts to reduce HI-induced consequences have failed in the clinical
setting. Therefore, it is imperative to create translatable studies that incorporate unique
characteristics of the immature brain, such as its anatomical structure, physiological
function, cellular composition, and its response to injury [14, 25, 27-36].
The specific objective of this study was to determine a mechanism by which
rOPN affected BBB permeability and brain edema in a well-established animal model of
neonatal HI. Our data demonstrate that administration of rOPN improves recovery after
neonatal HI by stabilization of the BBB, possibly via integrin receptor signaling pathway.
The long-term goal of this study is to provide a further basis for the clinical translation of
rOPN as an effective therapeutic option with long-term benefits.
In summary, this study showed that OPN protected the BBB following nHI, and
this was reversed by Rac1 inhibitor (NSC23766). The mechanisms mediating this
neuroprotection warrant further study.
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CHAPTER SIX
GENERAL DISCUSSION AND CONCLUSION
Summary of Key Findings
In the previous chapters we were able to demonstrate that IFNβ, G-CSF, and OPN
were able to confer neuroprotection after HIE [1, 2]. Also we reviewed and discussed
some of the impediments to developing neuroprotective strategies and the future of the
field [3].
Our findings showed that intranasal administration of IFNβ was able to reduce
neuronal apoptosis by activating the Jak1/Stat3/Bcl-2 pathway 24 hours post injury. We
determined that IFNβ treatment induces Stat3 activation and leads to increased
expression of Bcl-2 leading to a decrease in cleaved caspase-3 expression and neuronal
degeneration. IFNβ was also able to reduce brain infarction volumes, increase post-injury
weight, and improve short-term neurobehavior. Also Stat3 inhibition showed a reversal in
the protective effects of IFNβ treatment. Our results also demonstrated that
administration of G-CSF was able to reduce neuroinflammation and BBB disruption via
the G-CSFR/PI3K/Akt pathway activation and subsequent GSK-3β inactivation
following HIE. Moreover, G-CSF was able to decrease the expression of proinflammatory (IKKβ, NF-κB, TNF-α, IL-1β, and IL-12) while also increasing the
expression of IL-10, an anti-inflammatory cytokine [1]. We also found that OPN was
able to improve brain edema and reduce blood-brain barrier permeability following HIE
as well [2]. Our data suggests that OPN improves recovery and stabilizes the BBB after
neonatal HIE via the integrin receptor signaling pathway, since OPN mediated protection
was reversed when a RAC1 inhibitor was applied [2].
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How Our Findings Advance the Field?
Our scientific experiments and review article publications have been able to
significantly contribute to the field of neonatal HIE. We were able to effectively discuss
how to develop neuroprotective strategies and translation of experimental results in HIE,
the many limitations and challenges to create appropriate study designs, drug
administration, and usages in neonates. We also identified understudied targets after HIE,
neuroprotective molecules, recent trials being conducted in the clinical setting, and future
directions [3]. Also we explored and analyzed the current information concerning
isoflurane as an neuroprotective agent after neonatal HIE [4]. Our study was also the first
to explore the effects of IFNβ treatment after neonatal HIE, as well as the first to
characterize that IFNβ reduces neuronal apoptosis via the Jak1/Stat3/Bcl-2 pathway after
HIE. We also helped assist in the basic science research foundation of G-CSF and OPN,
since we found that G-CSF treatment reduces BBB disruption via GCSFR/PI3K/Akt/GSK-3β pathway and that rOPN stabilizes the BBB via the integrin
receptor [1, 2]. Our findings in these areas have produced the need for future studies to
further characterize and translate G-CSF and rOPN has possible clinical treatments. For
example further studies to examining the role of G-CSF in reducing cerebral edema and
the mechanisms by which G-CSF-mediated GSK-3β inactivation decreases VCAM and
ICAM and increases the expression of claudins should be explored. Also the antiapoptotic and anti-inflammatory properties and mechanisms of rOPN should also be
explored in the future.
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Current Limitations to Neuroprotective Strategies after HIE
Limitations to in Vitro and in Vivo
The distinct mechanisms of injury-induced damage in immature brain is
frequently studied, yet remains poorly understood, especially at early stages of
development. Also, a thorough evaluation method of the developmental and behavioral
sequelae after brain injury needs to be established [5].
In general, there are in vitro and in vivo models of experimental studies. In-vitro
studies are relatively inexpensive and often precede a following in vivo analysis, yet it
has its limitations of treating cells outside of their normal environment. Therefore, their
results may differ from in vivo effects [6]. If in vivo tests can confirm in vitro results, the
informative value of the results is more significant. In most cases, drug studies proven to
be effective in vitro, show ineffective in animal models. The underlying reason may be
drug delivery issues, toxicity, or other problems [7]. Even though several reviews
demonstrated poorly predictive value of animal models on human outcomes, those
experiments are mandatory especially in drug development before translation to clinical
trials [8-10].

Limitations to Animal Models
Especially since HIE and neonatal stroke are very heterogeneous entities,
therefore finding the ideal method to study this disorder remains a difficult task [11].
Ashwal and colleagues compared the HIE model by Rice-Vannucci and the neonatal
stroke filament occlusion model using MRI. Obviously, the stroke model injury was
defined on the ipsilateral middle cerebral artery territory, while more generalized and
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greater cortical ischemia occurred with the Rice-Vannucci method, even involving the
contralateral side in some cases [12].
Other new promising neonatal hypoxic-ischemic models have been introduced
recently, like a perinatal global ischemic brain injury model in rats providing intrapartum
hypoxia in rats [13]. Another perinatal method accomplished systemic hypoxic-ischemic
brain injury by cutting off the placenta blood supply to the fetuses to mimic brain damage
in early preterm newborns [14]. One model of postnatal permanent occlusion of the
middle cerebral artery was described using direct electrocoagulation aiming for a highly
reproducible, more consistent, and selective cortical infarction area [15].
The great variety of established models and promising new designs points out the
importance of carefully choosing the appropriate model, especially for testing possible
treatment strategies [16]. A few key points may be that the timing and nature of the
induced ischemic injuries vary tremendously in the different models. Additionally, the
translation from rodent studies to human trials are discussed broadly, because of diverse
and in some extent lacking neurological responses to sensorimotor cortex lesions when
compared to humans. This may demand non-human primate experiments for more
neurological similarity [17]. Thus, only one perinatal hypoxic-ischemic brain injury
model in primates has been developed so far, showing similar anatomical and cellular
pathology in cortex development, as in post-ischemic observations in newborns [18].
Although, biologically proximity to humans seems to be important in animal studies, over
95% of experiments in general were performed in rats and mice [19, 20]. Other points to
consider are the inevitable delays between symptom onset and start of treatment [21, 22]
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or the outcome assessment within days in animal models in contrast to after months in
patients [23].
Although much progress in experimental development and technology has been
made in the past few decades, the issue of discovering disease models, that can mimic
human pathophysiology sufficiently, remains an ongoing challenge [20, 24, 25].

Limitations to Central Nervous System Drug Delivery
Treatment strategies for central nervous system (CNS) diseases are challenged by
the drug delivery mechanisms for crossing the BBB [26]. The underlying reason, also
considered the bottleneck in CNS drug development, is in most cases since insufficient
attention to the prediction and assessment of the compounds ability to cross the BBB
[27]. Without solving the BBB problem, CNS drugs are limited to lipid-soluble and low
molecular weight (less than 400 Daltons) compounds. Progress in molecular
neuroscience might therefore lead to more availability of effective CNS therapeutics [28].
This demands research focusing on signaling pathways and trafficking mechanisms, as
involved brain transporters at the BBB and brain-cerebrospinal fluid-barrier [29].
In a recent publication, rapid and transient BBB disruptions were described after
HIE in neonatal mice associated with alteration of tight-junction proteins. This response
is often followed by activation of tightening compensatory mechanisms. More
understanding of this phenomenon might provide an opportunity window for compounds
to access the brain tissue easier after HIE [30].
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Limitations to Neonatal Drugs and Dosage
Additionally, in cases of neonatal HIE the clinical translation is more difficult
when compared to adult drug administrations, since most of the pharmacological
developments are approved only for adults and the regulations for pediatric and neonatal
use are highly restricted. Due to the small size and huge variability of pediatric patients,
neonatal pharmacotherapies are limited to mostly off label usage of compounds
developed for adults to extrapolate dosages [31-33]. Another issue besides the small
number yet huge variety of patients challenging clinical trials and regulations are possible
side effects, as in adverse drug reactions in the individualized neonatal treatment
strategies [34].
Progressive research in neonates might improve and optimize future ageappropriate treatment demanding tailored, personalized clinical pharmacological and
physiological understanding [35-38]. Further research topics involve drug excipients for
analyzing and initiating the safety and toxicity for pediatrics (STEP) database and the
European Study of Neonatal Excipient Exposure (ESNEE) initiative [39-41].

Conclusion and Future Perspectives
Although there have been significant strides in the basic sciences to create novel
neuroprotective and therapeutic strategies to combat HIE, there is still much more
research needed to be conducted in order to translate potential therapies. Some gaps in
our knowledge concerning the pathophysiology and the timing of important endogenous
neuroprotective and neuroregenerative mechanisms still exist. In order to make basic
science results more clinically relevant and translational, combinational therapies with
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hypothermia should be considered and studied. There is also a need for more biomarker
studies that can be used along with the brain imaging, and long-term neuro-assessments
[42, 43]. Thus, the field of neonatal HIE has many promising avenues and possibilities in
the realm of translational research.
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